

Jason M. Pogue  
Plymouth, MI, 48170  
Phone: 4126002706  
Email: jmpogue@med.umich.edu

**Education:**

Doctor of Pharmacy	University of Pittsburgh School of Pharmacy. Pittsburgh PA,2006
B.S. Chemistry	Gannon University, Erie, PA, 2002

**Licensure and Certification:**

Registered Pharmacist, Pennsylvania, RP441221	2006 - Present
Registered Pharmacist, Michigan, 5302038100	2007 – Present
Board Certified Infectious Diseases Pharmacist	2018 – 2024
Board Certified Pharmacotherapy Specialist (BCPS)	2007 – 2021
• Added qualifications in Infectious Diseases	2009 – 2021

**Pharmacy Experience:**

Clinical Pharmacist, Infectious Diseases – Michigan Medicine	2019 – Present
• Ann Arbor, Michigan	
Clinical Pharmacist, Infectious Diseases - Sinai-Grace Hospital	2008 – 2019
• Detroit, Michigan	
PGY – 2 Infectious Diseases Resident	2007 – 2008
• University of Michigan Health Systems, Ann Arbor, Michigan	
PGY – 1 Pharmacy Practice Resident	2006 – 2007
• University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania	

**Faculty Appointments:**

Clinical Professor	2019 – Present
• University of Michigan College of Pharmacy, Ann Arbor, Michigan	
Clinical Assistant Professor of Medicine	2009 – 2019
• Wayne State University School of Medicine, Detroit, Michigan	
Adjunct Clinical Assistant Professor	2009 – 2019
• University of Michigan College of Pharmacy, Ann Arbor, MI	
Associate Clinical Professor	2009 – 2019

- University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania

Adjunct Clinical Instructor

2007 – 2009

- University of Michigan College of Pharmacy, Ann Arbor, MI

### **Publications:**

163. Dorazio AJ, Kline EG, Squires KM, Shah S, Van Tyne D, Wu JY, **Pogue JM**, Shields RK. Ceftazidime-avibactam resistance evolution in *Pseudomonas aeruginosa* and implications for cross-resistance to other novel  $\beta$ -lactams. *Antimicrob Agents Chemother*. 2026 May 6;70(5):e0191025. doi: 10.1128/aac.01910-25. Epub 2026 Apr 6. PMID: 41940815; PMCID: PMC13148059.
162. Sheets AJ, Dennison J, **Pogue JM**, Kaye KS, Perry C, Millns H, Díaz-Regañón J, Janmohamed S. Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies. *Clin Infect Dis*. 2026 Apr 30;82(4):e684-e692. doi: 10.1093/cid/ciaf722. PMID: 41495938; PMCID: PMC13131927.
161. Bhavnani SM, Hammel JP, Onufrak NJ, **Pogue JM**, Jones RN, Sader HS, Drusano GL, Bradley JS, Andes DR, Craig WA, Ambrose PG. Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and *Pseudomonas aeruginosa*. *Open Forum Infect Dis*. 2025 Nov 26;12(12):ofaf426. doi: 10.1093/ofid/ofaf426. PMID: 41311914; PMCID: PMC12651555.
160. Bhavnani SM, Hammel JP, Onufrak NJ, **Pogue JM**, Jones RN, Sader HS, Drusano GL, Bradley JS, Andes DR, Craig WA, Ambrose PG. Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and *Pseudomonas aeruginosa*: Brief Summary. *Open Forum Infect Dis*. 2025 Nov 26;12(12):ofaf427. doi: 10.1093/ofid/ofaf427. PMID: 41311911; PMCID: PMC12651546.
159. Lavoie T, Sierra T, Daffinee K, **Pogue JM**, Achour B, LaPlante K. Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant *Enterobacter cloacae*. *Antimicrob Agents Chemother*. 2025 Dec 10;69(12):e0090625. doi: 10.1128/aac.00906-25. Epub 2025 Nov 19. PMID: 41258724; PMCID: PMC12691640.
158. Dorazio AJ, Aitken SL, Pierce VM, Kline EG, Squires KM, **Pogue JM**, Shields RK. First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in *Pseudomonas aeruginosa*. *Clin Infect Dis*. 2026 Feb 9;82(1):44-48. doi: 10.1093/cid/ciaf638. PMID: 41251222.
157. Wangchinda W, Wu JY, Abbo LM, Ackley R, Bartley P, Gilboa M, Harrington J, Jaffa R, Klatt ME, Kline EG, Kubat RC, Lepak AJ, McCreary EK, Miller WR, Pearson JC, Shah S, Tran TT, Vega A, Vendetti M, Yucel E, **Pogue JM**, Shields RK. Effectiveness of imipenem-relebactam for multidrug-resistant *Pseudomonas aeruginosa* in pneumonia and bloodstream infections in the United States (MIRAGE). *Antimicrob Agents Chemother*. 2025 Dec 10;69(12):e0132525. doi: 10.1128/aac.01325-25. Epub 2025 Nov 7. PMID: 41201892; PMCID: PMC12691631.
156. Horcajada JP, Gales AC, Isler B, Kaye KS, Kwa A, Landersdorfer CB, Montero MM, Oliver A, **Pogue JM**, Shields RK, Villegas MV, Yahav D, Paterson DL. Current and future options for the treatment of serious infections due to carbapenem-resistant *Pseudomonas aeruginosa*. *Clin Microbiol Rev*. 2025 Dec 11;38(4):e0023324. doi: 10.1128/cmr.00233-24. Epub 2025 Oct 9. PMID: 41065368; PMCID: PMC12697150.
155. Murphy AA, Indah R, Yufika A, Ichsan I, Liansyah TM, Harapan H, Birchok D, **Pogue JM**, Khairadini

- F, Wagner AL. Understanding the influence of religious and safety concerns on childhood measles and pertussis vaccination: a study conducted in Aceh, Indonesia, 2022. *BMC Infect Dis.* 2025 Sep 26;25(1):1140. doi: 10.1186/s12879-025-11448-7. PMID: 41013359; PMCID: PMC12465582.
154. Horcajada JP, Gales A, Isler B, Kaye KS, Kwa AL, Landersdorfer CB, Montero MM, Oliver A, **Pogue JM**, Shields RK, Villegas MV, Yahav D, Paterson DL. How do I manage difficult-to-treat *Pseudomonas aeruginosa* infections? Key questions for today's clinicians. *Clin Microbiol Infect.* 2025 Nov;31(11):1797-1806. doi: 10.1016/j.cmi.2025.08.018. Epub 2025 Aug 23. PMID: 40854462.
153. **Pogue JM**, Harrington J, Wangchinda W, Kaye KS. New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. *Antimicrob Agents Chemother.* 2025 Oct;69(10):e0108624. doi: 10.1128/aac.01086-24. Epub 2025 Aug 22. PMID: 40844462; PMCID: PMC12486857.
152. Huralaska M, **Pogue JM**, Rybak M, Abdul-Mutakabbir JC, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett DH, Patel G, Calfee DP, Leibovici L, Power L, Munoz-Price S, Shaikh H, Susick L, Latack K, Chiou C, Divine G, Ghazyaran V, Kaye KS. The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens. *Clin Infect Dis.* 2026 Mar 17;82(3):391-398. doi: 10.1093/cid/ciaf398. PMID: 40682801; PMCID: PMC13016684.
151. **Pogue JM**, van Duin D. The Antibiotic Pipeline Has Delivered for Drug-Resistant Gram-Negative Pathogens, Now Global Access Must Follow. *Clin Infect Dis.* 2025 Dec 24;81(5):889-890. doi: 10.1093/cid/ciaf262. PMID: 40581754.
150. Hanafin PO, Mahadevan R, Rao GG, Zavascki AP, Sandri AM, Kwa A, Scheetz MH, Kubin CJ, Shah J, Cherng BPZ, Yin MT, Wang J, Wang L, Calfee DP, Bolon M, Purcell AW, Nation RL, **Pogue JM**, Li J, Kaye KS. Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity. *Clin Pharmacol Ther.* 2025 Oct;118(4):841-852. doi: 10.1002/cpt.3729. Epub 2025 Jun 16. PMID: 40524377; PMCID: PMC12353974.
149. Dorazio AJ, Kline EG, Squires KM, **Pogue JM**, Van Tyne D, Shields RK. Restoring ceftolozane susceptibility: a role for diazabicyclooctane  $\beta$ -lactamase inhibitors? *Antimicrob Agents Chemother.* 2025 Mar 5;69(3):e0154324. doi: 10.1128/aac.01543-24. Epub 2025 Jan 28. PMID: 39873500
148. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Satola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, **Pogue JM**; PRECEDENT Network. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the USA (CACTUS): a multicentre, retrospective, observational study. *Lancet Infect Dis.* 2025 May;25(5):574-584. doi: 10.1016/S1473-3099(24)00648-0.
147. Wangchinda W, Aitken SL, Klatt ME, Lephart PR, Smith AB, **Pogue JM**. A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Pneumonia Caused by Gram-Negative Bacteria in Intensive Care Units: Unit-Specific Combination Antibigrams Versus Patient-Specific Risk Factors. *Open Forum Infect Dis.* 2024 Oct 30;11(11):ofae643. doi: 10.1093/ofid/ofae643. PMID: 39582504
146. Shah S, Kline EG, Haidar G, Squires KM, **Pogue JM**, McCreary EK, Ludwig J, Clarke LG, Stellfox M,

Van Tyne D, Shields RK. Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant *Pseudomonas aeruginosa* bacteremia or pneumonia. *Clin Infect Dis*. 2025 Feb 5;80(1):24-28. doi: 10.1093/cid/ciae332. PMID: 38902935.

145. Lodise TP, Bhavnani SM, Ambrose PG, Sader HS, Andes DR, **Pogue JM**. Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing. *Clin Infect Dis*. 2024 Dec 17;79(6):1354-1362. doi: 10.1093/cid/ciae328. PMID: 38902929.

144. Aitken SL, Pierce VM, **Pogue JM**, Kline EG, Tverdek FP, Shields RK. The growing threat of NDM-producing *E. coli* with penicillin-binding protein 3 mutations in the United States - is there a potential role for durlobactam? *Clin Infect Dis*. 2024 Oct 15;79(4):834-837. doi: 10.1093/cid/ciae229. PMID: 38661186.

143. Wangchinda W, **Pogue JM**, Thamlikitkul V, Leelawattanachai P, Koomanachai P, Pai MP. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections. *J Antimicrob Chemother*. 2024 Jun 3;79(6):1372-1379. doi: 10.1093/jac/dkae111. PMID: 38597137.

142. Wangchinda W, Kaye KS, Patel TS, Albin OR, Saravolatz L 2nd, Petrie JG, **Pogue JM**. A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended  $\beta$ -lactam-resistant *Pseudomonas aeruginosa*. *J Antimicrob Chemother*. 2024 Jun 3;79(6):1337-1345. doi: 10.1093/jac/dkae104. PMID: 38581308.

141. Justo JA, **Pogue JM**. Is it time to join the oral antibiotics bandwagon? *Lancet Infect Dis*. 2024 May;24(5):445-447. doi: 10.1016/S1473-3099(24)00032-X. Epub 2024 Jan 17. Erratum in: *Lancet Infect Dis*. 2024 May;24(5):e281. doi: 10.1016/S1473-3099(24)00255-X. PMID: 38244558.

140. **Pogue JM**, Aitken SL. Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury? *Open Forum Infect Dis*. 2023 Dec 18;11(1):ofad645. doi: 10.1093/ofid/ofad645. PMID: 38239847; PMCID: PMC10795513.

139. Yassin A, Huralska M, **Pogue JM**, Dixit D, Sawyer RG, Kaye KS. State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms. *Clin Infect Dis*. 2023 Nov 11;77(9):e46-e56. doi: 10.1093/cid/ciad499. PMID: 37738671.

138. Albin OR, **Pogue JM**, Wunderink RG, Kaye KS. Which trial do we need? Combination antimicrobial therapy for hospital-acquired bacterial pneumonia caused by *Pseudomonas aeruginosa*. *Clin Microbiol Infect*. 2024 Feb;30(2):162-164. doi: 10.1016/j.cmi.2023.07.007. Epub 2023 Jul 8. PMID: 37429434.

137. Wangchinda W, **Pogue JM**. Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2023 Jul 18;67(7):e0047523. doi: 10.1128/aac.00475-23. Epub 2023 Jun 13. PMID: 37310216; PMCID: PMC10353471.

136. Hanafin PO, Kwa A, Zavascki AP, Sandri AM, Scheetz MH, Kubin CJ, Shah J, Cherng BPZ, Yin MT, Wang J, Wang L, Calfee DP, Bolon M, **Pogue JM**, Purcell AW, Nation RL, Li J, Kaye KS, Rao GG. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalised patients. *Clin Microbiol Infect*. 2023 May 20:S1198-743X(23)00242-2. doi: 10.1016/j.cmi.2023.05.018. Epub ahead of print.

135. Tran NN, Mynatt RP, Kaye KS, Zhao JJ, **Pogue JM**. Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia.

Open Forum Infect Dis. 2023 Mar 27;10(4):ofad170. doi: 10.1093/ofid/ofad170.

134. Lepak AJ, Trang M, Hammel JP, Sader HS, Bhavnani SM, VanScoy BD, **Pogue JM**, Ambrose PG, Andes DR; United States Committee on Antimicrobial Susceptibility Testing. Development of Modernized *Acinetobacter baumannii* Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches. *Antimicrob Agents Chemother*. 2023 Apr 18;67(4):e0145222. doi: 10.1128/aac.01452-22. Epub 2023 Mar 22.

133. Kaye KS, Naas T, **Pogue JM**, Rossolini GM. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales. *Infect Dis Ther*. 2023 Mar;12(3):777-806. doi: 10.1007/s40121-023-00773-6. Epub 2023 Feb 25.

132. Kaye KS, Machaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Stevenson K, Susick L, Latack K, Daniel J, Chiou C, Divine GW, Ghazyaran V, **Pogue JM**. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. *NEJM Evid*. 2023 Jan;2(1):10.1056/evidoa2200131. doi: 10.1056/evidoa2200131. Epub 2022 Dec 6. PMID: 37538951; PMCID: PMC10398788.

131. Mahoney MV, Bhagat H, Christian R, Del Rio C, Hohmeier KC, Klepser ME, **Pogue JM**. Pharmacists as important prescribers of coronavirus disease 2019 (COVID-19) antivirals. *Antimicrob Steward Healthc Epidemiol*. 2022 Jul 11;2(1):e112. doi: 10.1017/ash.2022.248.

130. Lee TC, **Pogue JM**, McCreary EK, Morris AM. What is the place in therapy for nirmatrelvir/ritonavir? *BMJ Evid Based Med*. 2022 Nov 16:bmjebm-2022-112064. doi: 10.1136/bmjebm-2022-112064. Epub ahead of print.

129. Albin OR, Kaye KS, McCreary EK, **Pogue JM**. Less Is More? Antibiotic Treatment Duration in *Pseudomonas aeruginosa* Ventilator-Associated Pneumonia. *Clin Infect Dis*. 2023 Feb 18;76(4):745-749. doi: 10.1093/cid/ciac784

128. **Pogue JM**, McCreary EK. Monoclonals for patients hospitalised with COVID-19. *Lancet Respir Med*. 2022 Oct;10(10):928-930. doi: 10.1016/S2213-2600(22)00222-3. Epub 2022 Jul 8.

127. Prescott HC, Seelye S, Wang XQ, Hogan CK, Smith JT, Kipnis P, Barreda F, Donnelly JP, **Pogue JM**, Iwashyna TJ, Jones MM, Liu VX. Temporal Trends in Antimicrobial Prescribing During Hospitalization for Potential Infection and Sepsis. *JAMA Intern Med*. 2022 Aug 1;182(8):805-813. doi: 10.1001/jamainternmed.2022.2291.

126. Gupta V, Yu KC, **Pogue JM**, Watts JA, Clancy CJ. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and *Pseudomonas aeruginosa* Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints. *Microbiol Spectr*. 2022 Jun 29;10(3):e0115822. doi: 10.1128/spectrum.01158-22. Epub 2022 May 31.

125. **Pogue JM**, Zhou Y, Kanakamedala H, Cai B. Burden of illness in carbapenem-resistant *Acinetobacter baumannii* infections in US hospitals between 2014 and 2019. *BMC Infect Dis*. 2022 Jan 6;22(1):36.

124. Heil EL, Bork JT, Abbo LM, Barlam TF, Cosgrove SE, Davis A, Ha DR, Jenkins TC, Kaye KS, Lewis JS 2nd, Ortwine JK, **Pogue JM**, Spivak ES, Stevens MP, Vaezi L, Tamma PD. Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. *Open Forum Infect Dis*. 2021 Oct 11;8(10):ofab434

123. Monogue ML, Heil EL, Aitken SL, **Pogue JM**. The role of tazobactam-based combinations for the management of infections due to extended-spectrum  $\beta$ -lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*. 2021 Oct;41(10):864-880.
122. Zhou S, Nagel JL, Kaye KS, LaPlante KL, Albin OR, **Pogue JM**. Antimicrobial Stewardship and the Infection Control Practitioner: A Natural Alliance. *Infect Dis Clin North Am*. 2021 Sep;35(3):771-787.
121. **Pogue JM**, Lauring AS, Gandhi TN, Marshall VD, Eschenauer GA, Nagel JL, Baang JH, Zhou S, Valesano AL, Petty LA. Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. *Open Forum Infect Dis*. 2021 May 23;8(7):ofab268.
120. Alosaimy S, Lagnf AM, Morrisette T, Jorgensen SCJ, Trinh TD, Zasowski EJ, Scipione MR, Zhao JJ, Mynatt R, Herbin S, Dhar S, Chopra T, Janisse J, Rebold N, **Pogue JM**, Rybak MJ. Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant *Staphylococcus aureus* Bacteremia: STAPH Study. *Open Forum Infect Dis*. 2021 May 23;8(7):ofab261.
119. Albin OR, **Pogue JM**, Petty LA, Kaye KS. Asymptomatic bacterisputia: Rethinking diagnostic stewardship in pneumonia. *Infect Control Hosp Epidemiol*. 2021 2021 Jun;42(6):737-739..
118. Albin OR, Henig O, Patel TS, Valley TS, **Pogue JM**, Petty LA, Mills JP, Brancaccio A, Martin ET, Kaye KS. Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. *Clin Infect Dis*. 2020 Dec 15;71(12):3033-3041.
117. Petty LA, Vaughn VM, Flanders SA, Patel T, Malani AN, Ratz D, Kaye KS, **Pogue JM**, Dumkow LE, Thyagarajan R, Hsaiky LM, Osterholzer D, Kronick SL, McLaughlin E, Gandhi TN. Assessment of Testing and Treatment of Asymptomatic Bacteriuria Initiated in the Emergency Department. *Open Forum Infect Dis*. 2020 Nov 3;7(12):ofaa537.

116. Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavošchi L, Steele VR, Henriksen AS, Longshaw C, Manissero D, Pecini R, **Pogue JM**. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. *Clin Microbiol Infect*. 2021 Jan 6:S1198-743X(20)30764-3.
115. Hua X, Li C, **Pogue JM**, Sharma VS, Karaiskos I, Kaye KS, Tsuji BT, Bergen PJ, Zhu Y, Song J, Li J. ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. *JMIR Mhealth Uhealth*. 2020 Dec 16;8(12):e20525.
114. Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, **Pogue JM**, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. 2021 Feb;21(2):213-225.
113. Yang Q, Pogue JM, Li Z, Nation RL, Kaye KS, Li J. Agents of Last Resort: An Update on Polymyxin Resistance. *Infect Dis Clin North Am*. 2020 Dec;34(4):723-750.
112. Vaughn VM, Gandhi TN, Chopra V, Petty LA, Giesler DL, Malani AN, Bernstein SJ, Hsaiky LM, **Pogue JM**, Dumkow L, Ratz D, McLaughlin ES, Flanders SA. Antibiotic Overuse after Hospital Discharge: A Multi-Hospital Cohort Study. *Clin Infect Dis*. 2020 Sep 11:ciaa1372.
111. Cwengros LN, Mynatt RP, Timbrook TT, Mitchell R, Salimnia H, Lephart P, **Pogue JM**. Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests. *Open Forum Infect Dis*. 2020 Jul 2;7(8):ofaa278.
110. Morrisette T, Lodise TP, Scheetz MH, Goswami S, **Pogue JM**, Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. *Infect Dis Ther*. 2020 Sep;9(3):561-572.
109. Ambrose PG, Bhavnani SM, Andes DR, Bradley JS, Flamm RK, **Pogue JM**, Jones RN. Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. *Open Forum Infect Dis*. 2020 Mar 13;7(7):ofaa084.
108. Davis MR, McCreary EK, **Pogue JM**. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. *Infect Dis Ther*. 2020 Sep;9(3):525-536.
107. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Luring AS, Hanauer DA, Martin E, Sharma P, Fung CM, **Pogue JM**. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Clin Infect Dis*. 2020 Jul 11.
106. Henig O, **Pogue JM**, Martin E, Hayat U, Ja'ara M, Kilgore PE, Cha R, Dhar S, Kaye KS. The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections. *Open Forum Infect Dis*. 2020 May 6;7(5):ofaa161.

105. McCreary EK, **Pogue JM**. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. *Open Forum Infect Dis*. 2020 Mar 23;7(4):ofaa105.
104. Heil EL, Aitken SL, Nix DE, Drew R, Rose WE, Davis SL, Justo JA, Fish DN, **Pogue JM**; Society of Infectious Diseases Pharmacists. Recommended Revisions to the National SEP-1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. *Pharmacotherapy*. 2020 Apr;40(4):368- 371.
103. **Pogue JM**, Heil EL. The Clinical Impact of a Negative Molecular  $\beta$ -Lactamase Gene Test for Enterobacteriaceae: Let's Not Let Perfect Be the Enemy of Really Good. *J Clin Microbiol*. 2020 Mar 25;58(4):e02098-19.
102. Wu JY, Srinivas P, **Pogue JM**. Cefiderocol: A Novel Agent for the Management of Multidrug- Resistant Gram-Negative Organisms. *Infect Dis Ther*. 2020 Mar;9(1):17-40.
101. Salimnia H, Veltman J, Chandrasekar PH, **Pogue JM**, Mynatt R, Salimnia T, Marshall SH, Hujer AM, Bonomo RA. Carbapenem-Susceptible *Klebsiella pneumoniae* and *Escherichia coli* Isolates Carrying a Truncated KPC Carbapenemase: a Challenge for Rapid Molecular Diagnostics. *J Clin Microbiol*. 2020 Feb 24;58(3):e01627-19.
100. Albin OR, Henig O, Patel TS, Valley TS, **Pogue JM**, Petty LA, Mills JP, Brancaccio A, Martin ET, Kaye KS. Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. *Clin Infect Dis*. 2020 Dec 15;71(12):3033-3041.
99. **Pogue JM**, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA, Ambrose PG. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). *Antimicrob Agents Chemother*. 2020 Jan 27;64(2).
98. Ortwine JK, Zasowski EJ, **Pogue JM**, Hanni C, Giuliano C, Casapao AM, Mynatt R, Rybak MJ. Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. *Infect Dis Ther*. 2019 Dec;8(4):627-640.
97. **Pogue JM**, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant *Pseudomonas Aeruginosa*. *Clin Infect Dis*. 2019 Sep 23.
96. **Pogue JM**, Heil EL. Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world. *Expert Opin Pharmacother*. 2019 Dec;20(17):2053-2057
95. **Pogue JM**, Tam VH. Toxicity in Patients. *Adv Exp Med Biol*. 2019; 1145:289-304.
94. Giordano PA, **Pogue JM**, Cammarata S. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. *Clin Infect Dis*. 2019 Apr 8;68(Supplement\_3): S223-S232.

93. Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, **Pogue JM**, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus. *Infect Dis Ther*. 2019 Jun;8(2):199-208.
92. Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, **Pogue JM**. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. *Drugs*. 2019 Feb;79(3):243- 269.
91. Tsuji BT, **Pogue JM**, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*. 2019 Jan;39(1):10-39
90. Henig O, Cooper CC, Kaye KS, Lephart P, Salimnia H, Taylor M, Hussain N, Hussain Z, Deeds K, Hayat U, Patel J, **Pogue JM**. The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification. *J Antimicrob Chemother*. 2019 Jan 1;74(Supplement\_1): i32-i39.
89. Henig O, Kaye KS, Chandramohan S, Cooper CC, Lephart P, Salimnia H, Taylor M, Pogue JM. The Hypothetical Impact of Accelerate Pheno (ACC) on Time to Effective Therapy and Time to Definitive Therapy for bloodstream infections due to drug-resistant Gram-negative bacilli. *Antimicrob Agents Chemother*. 2018 Dec 17
88. Henig O, **Pogue JM**, Cha R, Kilgore PE, Hayat U, Ja'ara M, Ali RM, Mahboob S, Pansare R, Deeds K, Joarder B, Kandala H, Dhar S, Kaye KS. Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area with a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy. *Open Forum Infect Dis*. 2018 Sep 27;5(11).
87. Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, Rybak MJ, **Pogue JM**. Making the change to area under the curve-based vancomycin dosing. *Am J Health Syst Pharm*. 2018 Dec 15;75(24):1986-1995.
86. Petty LA, Henig O, Patel TS, **Pogue JM**, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. *Infect Drug Resist*. 2018 Sep 12; 11:1461-1472.
85. Jorgensen SCJ, McDonald P, Mynatt RP, **Pogue JM**, Lerner SA, Dhar S, Salimnia H, Rybak MJ. Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-

resistant *Serratia marcescens* and *Enterobacter aerogenes* bacteraemia in a haemodialysis patient. *J Antimicrob Chemother.* 2018 Dec 1;73(12):3529-3531.

84. **Pogue JM**, Bonomo RA, Kaye KS. Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations. *Clin Infect Dis.* 2018 Jul 18.

83. Barber KE, **Pogue JM**, Warnock HD, Bonomo RA, Kaye KS. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. *J Antimicrob Chemother.* 2018 Sep 1;73(9):2405-2410.

82. Patel TS, **Pogue JM**, Mills JP, Kaye KS. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. *Future Microbiol.* 2018 Jul; 13:971- 983.

81. **Pogue JM**, Heil EL, Lephart P, Johnson JK, Mynatt RP, Salimnia H, Claeys KC. An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities. *Antimicrob Agents Chemother.* 2018 Apr 26;62(5).

80. Claeys KC, Heil EL, **Pogue JM**, Lephart PR, Johnson JK. The Verigene dilemma: gram-negative polymicrobial bloodstream infections and clinical decision making. *Diagn Microbiol Infect Dis.* 2018 Feb 2.

79. Zasowski EJ, Murray KP, Trinh TD, Finch NA, **Pogue JM**, Mynatt RP, Rybak MJ. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. *Antimicrob Agents Chemother.* 2017 Dec 21;62(1).

78. Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, **Pogue JM**, Rybak MJ. The Impact of Vancomycin Area Under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity: a Quasi-Experiment. *Antimicrob Agents Chemother.* 2017 Nov 22;61(12).

77. Shorr AF, **Pogue JM**, Mohr JF. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections. *Expert Rev Anti Infect Ther.* 2017 Oct;15(10):935-945.

76. Dobson EL, Klepser ME, **Pogue JM**, Labreche MJ, Adams AJ, Gauthier TP, Turner RB, Su CP, Jacobs DM, Suda KJ; SIDP Community Pharmacy Antimicrobial Stewardship Task Force. Outpatient antibiotic stewardship: Interventions and opportunities. *J Am Pharm Assoc (2003).* 2017 Jul - Aug;57(4):464-473.

75. Klepser ME, Dobson EL, **Pogue JM**, Labreche MJ, Adams AJ, Gauthier TP, Turner RB, Su CP, Jacobs DM, Suda KJ; SIDP Community Pharmacy Antimicrobial Stewardship Task Force. A call to action for outpatient antibiotic stewardship. *J Am Pharm Assoc (2003).* 2017 Jul - Aug;57(4):457- 463.

74. Huang D, Yu B, Diep JK, Sharma R, Dudley M, Monteiro J, Kaye KS, **Pogue JM**, Abboud CS, Rao GG. *In Vitro* Assessment of Combined Polymyxin B and Minocycline Therapy against

*Klebsiella pneumoniae* Carbapenemase (KPC)-Producing *K. pneumoniae*. *Antimicrob Agents Chemother*. 2017 Jun 27;61(7).

73. Onufrak NJ, Rao GG, Forrest A, **Pogue JM**, Scheetz MH, Nation RL, Li J, Kaye KS. Critical Need for Clarity in Polymyxin B Dosing. *Antimicrob Agents Chemother*. 2017 Apr 24;61(5).

72. Lashinsky JN, Henig O, **Pogue JM**, Kaye KS. Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant *A. baumannii*: A Review. *Infect Dis Ther*. 2017 Jun;6(2):199-211.

71. **Pogue JM**, Ortwine JK, Kaye KS. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing. *Clin Microbiol Infect*. 2017 Feb 24.

70. Sharma R, Patel S, Abboud C, Diep J, Ly NS, **Pogue JM**, Kaye KS, Li J, Rao GG. Polymyxin B in combination with meropenem against carbapenemase-producing *Klebsiella pneumoniae*: pharmacodynamics and morphological changes. *Int J Antimicrob Agents*. 2017 Feb;49(2):224- 232.

69. Navalkele B, **Pogue JM**, Karino S, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Koons J, Hussain T, Perry W, Evans R, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Kaye KS. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin- Tazobactam Compared to Those on Vancomycin and Cefepime. *Clin Infect Dis*. 2017 Jan 15;64(2):116-123.

68. **Pogue JM**, Ortwine JK, Kaye KS. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? *Int J Antimicrob Agents*. 2016 Dec;48(6):622-626.

67. **Pogue JM**, Ortwine JK, Kaye KS. Editorial Commentary: Colistin Dosing: Does the Fun Ever Start? *Clin Infect Dis*. 2016 Dec 15;63(12):1613-1614.

66. Nagel JL, Kaye KS, LaPlante KL, **Pogue JM**. Antimicrobial Stewardship for the Infection Control Practitioner. *Infect Dis Clin North Am*. 2016 Sep;30(3):771-84.

65. Thaden JT, **Pogue JM**, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. *Virulence*. 2016 Jul 6:1-14.

64. Hasassri ME, Boyce TG, Norgan A, Cunningham SA, Jeraldo PR, Weissman S, Patel R, Banerjee R, **Pogue JM**, Kaye KS. An Immunocompromised Child with Bloodstream Infection Caused by Two *Escherichia coli* Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase. *Antimicrob Agents Chemother*. 2016 May 23;60(6):3270-5.

63. Kaye KS, **Pogue JM**, Tran TB, Nation RL, Li J. Agents of Last Resort: Polymyxin Resistance. *Infect Dis Clin North Am*. 2016 Jun;30(2):391-414.

62. Karino S, Kaye KS, Navalkele B, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Martin ET, Mynatt RP, Murray KP, Rybak MJ, **Pogue JM**. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. *Antimicrob Agents Chemother*. 2016 May 23;60(6):3743-50.

61. Malani AN, Brennan BM, Collins CD, Finks J, **Pogue JM**, Kaye KS. Antimicrobial Stewardship Practices in Michigan Long-Term Care Facilities. *Infect Control Hosp Epidemiol*. 2016 Feb;37(2):236-7.
60. Kaye KS, **Pogue JM**. Infections caused by resistant Gram-negative bacteria: epidemiology and management. *Pharmacotherapy*. 2015. Oct;35(10):949-62.
59. Collins CD, Miller DE, Kenney RM, Mynatt RP, Tiberg MD, Cole K, *Sutton JD*, **Pogue JM**. The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals. *Hosp Pharm*. 2015 Mar;50(3):180-4.
58. **Pogue JM**, Ortwine JK, Kaye KS. Optimal usage of colistin: Are we any closer? *Clin Infect Dis*. 2015 Dec 15;61(12):1778-80.
57. Ortwine JK, Sutton JD, Kaye KS, **Pogue JM**. Strategies for the safe use of colistin. *Expert Rev Anti Infect Ther*. 2015 Oct;13(10):1237-47.
56. Morrill HJ, **Pogue JM**, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant enterobacteriaceae infections. *Open Forum Infect Dis*. 2015 May 5;2(2): ofv050.
55. Sutton JD, Mynatt RP, Kaye KS, Murray KP, Rybak MJ, **Pogue JM**. Nephrotoxicity comparison of two commercially available generic products. *Antimicrob Agents Chemother*. 2015 Sep;59(9):5470-4.
54. Chopra T, Marchaim D, Johnson PC, Chalana IK, Tamam Z, Mohammed M, Alkatib S, Tansek R, Chaudhry K, Zhao JJ, **Pogue JM**, Kaye KS. Risk factors for bloodstream infection caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: A focus on antimicrobials including cefepime. *Am J Infect Control*. 2015 Jul 1;43(7):719-23.
53. **Pogue JM**, Kaye KS, Cohen DA, Marchaim D. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. *Clin Microbiol Infect*. 2015 Apr;21(4):302-12.
52. Barber KE, King ST, Stover KR, **Pogue JM**. Therapeutic options for vancomycin-resistant enterococcal bacteremia. *Expert Rev Anti Infect Ther*. 2015 Mar;13(3):363-77.
51. **Pogue JM**, Cohen DA, Marchaim D. Editorial Commentary: Polymyxin-Resistant *Acinetobacter baumannii*: Urgent Action Needed. *Clin Infect Dis*. 2015 May 1;60(9):1304-7.
50. **Pogue JM**, Rotschafer JC. Polymyxins in 2015: it's like déjà vu all over again. *Pharmacotherapy*. 2015 Jan;35(1):9-10.
49. **Pogue JM**, Neelakanta A, Mynatt RP, et.al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. *Clin Infect Dis*. 2014 Dec 1;59 Suppl 6: S388-93.
48. Ortwine JK, Kaye KS, Li J, **Pogue JM**. Colistin: Understanding and Applying Recent Pharmacokinetic Advances. *Pharmacotherapy*. 2015 Jan;35(1):11-6.

47. Ortwine JK, **Pogue JM**, Faris J. Pharmacokinetics and Pharmacodynamics of Antibacterial and Antifungal Agents in Adult Patients With Thermal Injury: A Review of Current Literature. *J Burn Care Res.* 2015 Mar-Apr;36(2): e72-84.

46. Chopra T, Marchaim D, Johnson PC, Awali RA, Doshi H, Chalana I, Davis N, Zhao JJ, **Pogue JM**, Parmar S, Kaye KS. Risk factors and outcomes for patients with bloodstream infection due to *Acinetobacter baumannii-calcoaceticus* complex. *Antimicrob Agents Chemother.* 2014 Aug;58(8):4630-5.

45. Bogan C, Kaye KS, Chopra T, Hayakawa K, **Pogue JM**, et.al. Outcomes of carbapenem- resistant Enterobacteriaceae isolation: matched analysis. *Am J Infect Control.* 2014 Jun;42(6):612-20.

44. Hayakawa K, Martin ET, Gudur UM, Marchaim D, Dalle D, Alshabani K, Muppavarapu KS, Jaydev F, Bathina P, Sundaragiri PR, Rajuri SD, Khatri J, **Pogue JM**, Lephart PR, Rybak MJ, Kaye KS. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. *Antimicrob Agents Chemother.* 2014 Jul;58(7):3968-75.

43. Farooq S, Hayakawa K, Marchaim D, **Pogue JM**, Kaye KS. Extended-spectrum  $\beta$ -lactamase- producing *Escherichia coli* isolation among older adults: epidemiology and outcomes. *Am J Infect Control.* 2014 May;42(5):565-8.

42. **Pogue JM**, Potoski BA, Postelnick M, et.al. Bringing the "power" to Cerner's PowerChart for antimicrobial stewardship. *Clin Infect Dis.* 2014 Aug;59(3):416-24.

41. Brennan BM, Coyle JR, Marchaim D, **Pogue JM**, et.al. Statewide surveillance of carbapenem- resistant enterobacteriaceae in Michigan. *Infect Control Hosp Epidemiol.* 2014 Apr;35(4):342-9.

40. Marchaim D, **Pogue JM**, Tzuman O, et.al. Major variation in MICs of tigecycline in Gram- negative bacilli as a function of testing method. *J Clin Microbiol.* 2014 May;52(5):1617-21.

39. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, **Pogue JM**, Rybak MJ. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. *Antimicrob Agents Chemother.* 2014 May;58(5):2541-6.

38. **Pogue JM**, Mynatt RP, Marchaim D, Zhao JJ, Barr VO, Moshos J, Sunkara B, Chopra T, Chidurala S, Kaye KS. Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with Gram-negative bacteremia. *Infect Control Hosp Epidemiol* 2014 Feb;35(2):132-8.

37. **Pogue JM**, Marchaim D, Chopra T, Bheemreddy S, Lee J, Mudegowdra NS, Chaudhry A, Kaye KS. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. *J Infect Public Health.* 2013 Nov 5.

36. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, Slim J, Hothi J, Ahmed H, **Pogue JM**, Zhao JJ, Kaye KS. Epidemiology of bloodstream infections caused

by *Acinetobacter baumannii* and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. *Antimicrob Agents Chemother*. 2013 Dec;57(12):6270-5.

35. **Pogue JM**, Kaye KS. Is there really no benefit to combination therapy with colistin? *Expert Rev Anti Infect Ther*. 2013 Sep;11(9):881-4.

34. Omotola AM, Li Y, Martin ET, Alshabani K, Yadav D, Sarkar M, Thapa SD, Kumar V, Mahabashya A, Ahmad S, Bhargava A, Marchaim D, **Pogue JM**, Rybak MJ, Kaye KS, Hayakawa K. Risk factors for and epidemiology of community onset vancomycin-resistant *enterococcus faecalis* in southeast Michigan. *Am J Infect Control*. 2013 Dec;41(12):1244-8.

33. Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K, Gudur UM, Pulluru H, Bathina P, Sundaragiri PR, Sarkar M, Kakarlapudi H, Ramasamy B, Nanjireddy P, Mohin S, Dasagi M, Datla S, Kuchipudi V, Reddy S, Shahani S, Upputuri V, Marrey S, Gannamani V, Madhanagopal N, Annangi S, Sudha B, Muppavarapu KS, Moshos JA, Lephart PR, **Pogue JM**, Bush K, Kaye KS. Epidemiology and Risk Factors for Isolation of *Escherichia coli* Producing CTX-M-Type Extended-Spectrum  $\beta$ -Lactamase in a Large U.S. Medical Center. *Antimicrob Agents Chemother*. 2013 Aug;57(8):4010-8.

32. **Pogue JM**, Marchaim D, Abreu-Lanfranco O, Sunkara B, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Martin ET, Dhar S, Kaye KS, Lephart PR. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant *Enterococcus*, Detroit, 2008-10. *J Antibiot (Tokyo)*. 2013 May 29.

31. **Pogue JM**, Mann T, *Barber KE*, Kaye KS. Carbapenem-resistant *Acinetobacter baumannii*: epidemiology, surveillance and management. *Expert Rev Anti Infect Ther*. 2013 Apr;11(4):383-93.

30. Hayakawa K, Marchaim D, Bathina P, Martin ET, **Pogue JM**, Sunkara B, Kamatam S, Ho K, Willis LB, Ajamoughli M, Patel D, Khan A, Lee KP, Suhrawardy U, Jagadeesh KK, Reddy SM, Levine M, Ahmed F, Omotola AM, Mustapha M, Moshos JA, Rybak MJ, Kaye KS. Independent risk factors for the co-colonization of vancomycin-resistant *Enterococcus faecalis* and methicillin-resistant *Staphylococcus aureus* in the region most endemic for vancomycin-resistant *Staphylococcus aureus* isolation. *Eur J Clin Microbiol Infect Dis*. 2013 Jun;32(6):815-20.

29. Kullar R, Davis SL, Kaye KS, Levine DP, **Pogue JM**, Rybak MJ. Implementation of an Antimicrobial Stewardship Pathway with Daptomycin for Optimal Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia. *Pharmacotherapy*. 2013 Jan;33(1):3-10.

28. Campbell ML, Marchaim D, **Pogue JM**, Sunkara B, Bheemreddy S, Bathina P, Pulluru H, Chugh N, Wilson MN, Moshos J, Ku K, Hayakawa K, Martin ET, Lephart PR, Rybak MJ, Kaye KS. Treatment of Methicillin-Resistant *Staphylococcus aureus* Infections with a Minimal Inhibitory Concentration of 2  $\mu$ g/mL to Vancomycin: Old (Trimethoprim/Sulfamethoxazole) versus New (Daptomycin or Linezolid) Agents. *Ann Pharmacother*. 2012 Dec;46(12):1587-97.

27. Hayakawa K, Marchaim D, **Pogue JM**, Ho K, Parveen S, Nanjireddy P, Sunkara B, Singla M, Jagadeesh KK, Moshos JA, Bommarito S, Mroue R, Farhat M, Obeid T, Chaudhry A, Vadlamudi G, Lephart PR, Martin ET, Rybak MJ, Kaye KS. Predictors and outcomes of linezolid-resistant

vancomycin-resistant *Enterococcus*: a case-case-control study. *Am J Infect Control*. 2012 Dec;40(10):e261-3.

26. Judge T, **Pogue JM**, Marchaim D, Ho K, Kamatam S, Parveen S, Tiwari N, Nanjireddy P, Bheemreddy S, Biedron C, Reddy SM, Khammam V, Chalana IK, Tumma RS, Collins V, Yousuf A, Lephart PR, Martin ET, Rybak MJ, Kaye KS, Hayakawa K. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. *Infect Control Hosp Epidemiol*. 2012 Dec;33(12):1250-4.

25. Hayakawa K, Marchaim D, Palla M, Gudur UM, Pulluru H, Bathina P, Alshabani K, Govindavarjulla A, Mallad A, Abbadi DR, Chowdary D, Kakarlapudi H, Guddati H, Das M, Kannekanti N, Vemuri P, Doddamani R, Mundra VR, Guddeti RR, Policherla R, Bai S, Lohithaswa S, Shashidharan SP, Chidurala S, Diviti S, Sukayogula K, Joseph M, **Pogue JM**, Lephart PR, Martin ET, Rybak MJ, Kaye KS. Epidemiology of Vancomycin-Resistant *Enterococcus faecalis*: a Case- Case-Control Study. *Antimicrob Agents Chemother*. 2013 Jan;57(1):49-55.

24. Alaniz C, **Pogue JM**. Vancomycin versus linezolid in the treatment of methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia: implications of the ZEPHYR trial. *Ann Pharmacother*. 2012 Oct;46(10):1432-5.

23. Martin ET, Tansek R, Collins V, Hayakawa K, Abreu-Lanfranco O, Chopra T, Lephart PR, **Pogue JM**, Kaye KS, Marchaim D. The carbapenem-resistant Enterobacteriaceae score: A bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients. *Am J Infect Control*. 2012 Aug 30.

22. Hayakawa K, Marchaim D, Divine GW, **Pogue JM**, et.al. Growing prevalence of *Providencia stuartii* associated with the increased usage of colistin at a tertiary health care center. *Int J Infect Dis*. 2012 Sep;16(9):e646-8.

21. Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, **Pogue JM**, et.al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. *Infect Control Hosp Epidemiol*. 2012 Aug;33(8):817-30.

20. Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, **Pogue JM**, et.al. Impact of cefepime therapy on mortality among patients with blood stream infections caused by extended spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. *Antimicrob Agents Chemother*. 2012 Jul;56(7):3936-42.

19. Ku K, **Pogue JM**, Moshos J, et.al. Retrospective evaluation of colistin versus tigecycline for the treatment of *Acinetobacter baumannii* and/or carbapenem-resistant Enterobacteriaceae infections. *Am J Infect Control*. 2012 Dec;40(10):983-7.

18. Hayakawa K, Marchaim D, Martin ET, Tiwari N, Yousuf A, Sunkara B, Pulluru H, Kotra H, Hasan A, Bheemreddy S, Sheth P, Lee DW, Kamatam S, Bathina P, Nanjireddy P, Chalana IK, Patel S, Kumar S, Vahia A, Ku K, Yee V, Swan J, **Pogue JM**, et.al. Comparison of the Clinical Characteristics and Outcomes Associated with Vancomycin-Resistant *Enterococcus faecalis* and Vancomycin-Resistant *E. faecium* Bacteremia. *Antimicrob Agents Chemother*. 2012 May;56(5):2452-8.

17. Marchaim D, Perez F, Lee J, Bheemreddy S, Hujer AM, Rudin S, Hayakawa K, Lephart PR, Blunden C, Shango M, Campbell ML, Varkey J, Manickam P, Patel D, **Pogue JM**, et.al. "Swimming in resistance": Co-colonization with carbapenem-resistant Enterobacteriaceae and *Acinetobacter baumannii* or *Pseudomonas aeruginosa*. *Am J Infect Control*. 2012 Feb 10.
16. Collins VL, Marchaim D, **Pogue JM**, et.al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae. *Antimicrob Agents Chemother*. 2012 Apr;56(4):2173-7.
15. Marchaim D, Chopra T, Bogan C, Bheemreddy S, Sengstock D, Jagarlamudi R, Malani A, Lemanek L, Moshos J, Lephart PR, Ku K, Hasan A, Lee J, Khandker N, Blunden C, Geffert SF, Moody M, Hiro R, Wang Y, Ahmad F, Mohammadi T, Faruque O, Patel D, **Pogue JM**, et.al. The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities. *Am J Infect Control*. 2012 Jan 26.
14. Marchaim D, Taylor AR, Hayakawa K, Bheemreddy S, Sunkara B, Moshos J, Chopra T, Abreu- Lanfranco O, Martin ET, **Pogue JM**, et.al. Hospital bath basins are frequently contaminated with multidrug-resistant human pathogens. *Am J Infect Control*. 2011 Dec 15.
13. **Pogue JM**, Lee J, Marchaim D, et.al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health-system. *Clin Infect Dis*. 2011 Nov;53(9):879-84.
12. Hayakawa, K, Marchaim D, Vidailac C, Lephart P, **Pogue JM**, et.al. Growing prevalence of vancomycin-resistant *Enterococcus faecalis* in the region with the highest prevalence of vancomycin-resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol*. 2011 Sep;32(9):922-4.
11. Marchaim D, Chopra T, Perez F, Hayakawa K, Lephart PR, Bheemreddy S, Blunden C, Hujer AM, Rudin S, Shango M, Campbell M, Varkey J, Slim J, Ahmad F, Patel D, Chen TY, **Pogue JM**, et.al. Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center. *Infect Control Hosp Epidemiol*. 2011 Sep;32(9):861-71.
10. **Pogue JM**, Marchaim D, Kaye D, Kaye KS. Revisiting older antibiotics in the era of multi-drug resistance. *Pharmacotherapy*. 2011 Sep;31(9):912-21.
9. Kullar R, Leonard SN, Davis SL, Delgado Jr. G, **Pogue JM**, Wahby KA, Falcione B, Rybak MJ. Validation of a vancomycin nomogram to achieve the vancomycin consensus guidelines suggested trough concentrations of 15 to 20 mg/L. *Pharmacotherapy*. May 2011; 31(5):441-8.
8. Saely S, Kaye KS, Fairfax MR, Chopra T, **Pogue JM** Investigation the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum beta-lactamase producing *Klebsiella Pneumoniae*. *Am J Infect Control*. 2011 Jun;39(5):390-5.
7. **Pogue JM**, Alaniz C, Carver P, Pleva M, Newton D, DePestel DD. The role of unit specific combination antibiograms for improving the selection of empiric therapy for Gram-negative pneumonia. *Infect Control Hosp Epidemiol*. 2011 Mar;32(3): 289-92.

6. Marchaim D, Chopra T, **Pogue JM**, Perez F, Hujer AM, Rudin S, Endimiani A, Navon-Venezia S, Hothi J, Slim J, Blunden C, Shango M, Lephart PR, Salimnia H, Reid D, Moshos J, Hafeez W, Bheemreddy S, Chen TY, Dhar S, Bonomo RA, Kaye KS. Outbreak of colistin-resistant, carbapenem-resistant *Klebsiella pneumoniae* in metropolitan Detroit, MI. *Antimicrob Agents Chemother*. 2011 Feb;55(2):593-9.
5. Kaye KS, Auwaeter P, Bosso JA, Dean NC, Doern GV, Kays MB, **Pogue JM**, Ritchie DJ, Wispelwey B. Strategies to address appropriate fluoroquinolone use in the hospital. *Hosp Pharm*. Nov 2010; 45(11):844-53.
4. **Pogue JM**, Potoski BA, Kaye KS. Aminoglycoside use in the intensive care unit and nephrotoxicity. *Antimicrob Agents Chemother*. 2010 Jun; 54(6):2750.
3. Reddy T, Chopra T, Marchaim D, **Pogue JM**, Alangaden G, Salimnia H, Boikov D, Navon- Venezia S, Akins R, Selman P, Dhar S, Kaye KS. Trends in Antimicrobial Resistance of *Acinetobacter baumannii* isolates from a Metropolitan Detroit Health System. *Antimicrob Agents Chemother*. 2010 March 8.
2. **Pogue JM**, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft versus host disease of the gastrointestinal tract. *Transpl Infect Dis*. 2009 Oct; 11(5) 467-70.
1. **Pogue JM**, Paterson DL, Pasculle AW, Potoski BA. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant enterococcus (VRE). *Infect Control Hosp Epidemiol*. 2007; 28(12) 1382-88.

### **Grant Support:**

#### **Ongoing:**

Co-Principal Investigator (with Ryan Shields, PharmD). Treatment Patterns and Clinical Outcomes for Patients with *Stenotrophomonas maltophilia* and Metallo-B-lactamase-producing Enterobacterales Infections in the United States (TRANSFORM). Abbvie Therapeutics. 0.15 FTE. 2025 - 2027

Co-Principal Investigator (with Ryan Shields, PharmD). Management strategies for *Acinetobacter baumannii* in the United States: Real-world evidence and clinical outcomes associated with Sulbactam-Durlobactam (TUNDRA). Entasis Therapeutics. 0.10 FTE. 2024 - 2026

Co-Principal Investigator (with Ryan Shields, PharmD). Ceftazidime-Avibactam versus Meropenem-Vaborbactam for the Treatment of Bloodstream Infections and/or Pneumonia due to Carbapenem-resistant Enterobacterales (CAMEL). Melinta Pharmaceuticals. 0.15 FTE. 2024 – 2026.

Co-Principal Investigator (with Ryan Shields, PharmD). Cefiderocol treatment Versus ceftolozane/tazobactam for the treatment of pneumonia and/or bloodstream Infections due to Multidrug-Resistant *Pseudomonas aeruginosa* (CONVINCE). Shionogi. 0.20 FTE. 2024 – 2026.

Co-Principal Investigator (with Ryan Shields, PharmD). Optimizing escalation: Ceftolozane/tazobactam versus treatment with traditional anti-pseudomonal  $\beta$ -lactams for pneumonia or bloodstream infections due to MDR *Pseudomonas aeruginosa* (STEWARDS). Merck Pharmaceuticals. 0.15 FTE. 2023 – 2025.

Co-Investigator (PI: Stephanie Taylor). Diagnostic Safety and Quality in Sepsis (DISQOS). Agency for Healthcare Research and Quality. 0.05 FTE. 2023 – 2028.

**Completed:**

Co-Principal Investigator (with Ryan Shields, PharmD). Effectiveness of Imipenem-Relebactam for Multi-Drug Resistant *Pseudomonas aeruginosa* Pneumonia and Bloodstream Infections in the United States. Merck Pharmaceuticals. 0.2 FTE. 2023 – 2024.

Co-Investigator (PI: Abram Wagner). Trusted Faces, Familiar Places. Center for Global Health Equity, University of Michigan. 0.05 FTE. 2023 – 2025.

Co-Principal Investigator (with Ryan Shields, PharmD). A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS). Merck Pharmaceuticals. 0.2 FTE support. 2022 – 2024.

Principal investigator, Clinical Pharmacy Coordinator. Principal Investigators Keith Kaye, MD and Jian Li, PhD. Optimizing clinical use of Polymyxin B: Teaching an Old Drug to Treat Superbugs. NIAID. 0.05 FTE support. 2021 – 2022.

Co-investigator, Clinical Pharmacy Coordinator. Principal Investigators Keith Kaye, MD and Jian Li, PhD. Optimizing clinical use of Polymyxin B: Teaching an Old Drug to Treat Superbugs. NIAID. 0.30 FTE support. 2015 – 2021.

Co-investigator, Clinical Pharmacy Coordinator. Principle investigator Keith Kaye, MD. Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli. National Institute of Allergy and Infectious Diseases (NIAID). DMID 10-0065. 0.5 FTE support. 2012 – 2021.

Consultant and co-investigator. Principle Investigator Krishna Rao, MD. A Comparison of Vancomycin and Fidaxomicin for the Treatment of *C. difficile* Associated Diarrhea in Patients Receiving Concomitant Antibiotics. Merck Pharmaceuticals. \$400/hour, 5-10 hours/year.

Co-Principle Investigator (with Federico Perez, MD). A Real-World Comparison of Ceftolozane/Tazobactam versus Polymyxin/Aminoglycoside Based Regimens for the Treatment of MDR/XDR *P. aeruginosa*. Merck Pharmaceuticals. 0.1 FTE support. 2017-2018

**Selected National and International Presentations:**

May 2026. The Society of Infectious Diseases Pharmacists and Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Workshop: How to critically evaluate literature and write a peer review.**

April 2026. The Society for Healthcare Epidemiology of America (SHEA) Spring Meeting. Orlando, FL. **Tough Bugs and New (and old) Drugs.**

April 2026. Top 5 Infectious Diseases International Symposium. Venice, Italy. **The latest on the treatment of MDR *P. aeruginosa*.**

October 2025. European Society of Intensive Care Medicine Annual Meeting. Munich, Germany. **Optimizing Nosocomial Pneumonia Management in the ICU.**

June 2025. Society of Infectious Diseases Pharmacists/ ESCMID PK/PD Study Group of Anti-Infectives Inaugural PK/PD Workshop. Madison, WI. **Revisiting the breakpoints for oral cephalosporins for (systemic) Enterobacterales**

May 2025. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Challenging Gram-negative Organisms.**

May 2025. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **What's New in PK/PD and Breakpoints**

April 2025. The Society for Healthcare Epidemiology of America (SHEA) Spring Meeting. Orlando, FL. **Tough Bugs and New (and old) Drugs.**

April 2025. Top 5 Infectious Diseases International Symposium. Venice, Italy. **Combination versus Monotherapy for severe *P. aeruginosa* infections: Do we really know anything?**

December 2024. USCAST Annual Meeting (Virtual). **Trimethoprim-Sulfamethoxazole (TMP-SMX) Susceptibility Test Interpretative Criteria (STIC) for Enterobacterales uncomplicated UTI.**

April 2024. American Burn Association Annual Meeting. Chicago, IL. **Difficult to Treat Resistance (DTR) *P. aeruginosa* and the role of novel beta-lactams.**

March 2024. Top 5 Infectious Diseases International Symposium. Venice, Italy. **Combination Therapy for Carbapenem-Resistant Enterobacterales (CRE).**

November 2023. Infectious Diseases Society of New Jersey and the Northern and Southern New Jersey Chapters of the Association for Professionals in Infection Control and Epidemiology Annual Meeting. Monroe township, NJ. **Antibiotic Stewardship Strategies in the Era of Increasing Antimicrobial Resistance.**

July 2023. Clinical Infectious Diseases Society of India Annual Meeting (CIDSCON). Chennai, India (presented virtually). **Antimicrobial Dosing Considerations in Critically Ill Patients.**

June 2023. American Society for Microbiology (ASM) Microbe Annual Meeting. Houston, TX. **Rising antibiotic resistance in the community and strategies required to control infection.**

June 2023. Illinois Summit on Antimicrobial Stewardship. Bloomington, IL. **Top Antimicrobial Stewardship Papers of 2022-2023.**

June 2023. South African Society of Clinical Pharmacy (SASOCP) Annual Meeting. Muldersdrift, South Africa. **Multi-Drug Resistant Gram-Negative Pathogens in South Africa: Problems and Solutions.**

June 2023. South African Society of Clinical Pharmacy (SASOCP) Annual Meeting. Muldersdrift, South Africa. **The role of the clinical pharmacist in pushing antimicrobial stewardship forward.**

May 2023. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Hot Topics: What Did You Miss in Infectious Diseases 2022-2023.** Presented with Erin McCreary, Pharm.D.

May 2023. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Different Organizations, Different Breakpoints: Making Sense of Recent Updates to Susceptibility Breakpoints from CLSI, EUCAST, and USCAST.**

December 2022. American Society of Health-Systems Pharmacists Annual Midyear Meeting. Las Vegas, NV. **Is there a role for combination therapy in the treatment of infections due to Gram-negative bacilli?**

October 2022. American College of Clinical Pharmacists Global Conference on Clinical Pharmacy. San Francisco, CA. **Management of difficult to treat bacterial pathogens: a focus on new treatment options.**

October 2022. ID week 2022. Washington D.C. **Using antibiograms to decrease time to appropriate therapy: We can do better.**

May 2022. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Oral Carbapenems are Coming: Are You Excited or Anxious?** Pro/con debate with Katie Barber, PharmD.

May 2022. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Treatment of Challenging Gram-Negative Infections.**

September 2021. ID week 2021 (virtual). **Antimicrobial resistance (AMR) in community-acquired uncomplicated urinary tract infection: does it exist? Does it matter?**

June 2021. ASM Microbe 2021 (Virtual). **Stewardship Strategies for Utilizing Rapid Diagnostic Tests to Optimize the Management of Gram-Negative Bloodstream Infections**

May 2021. Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting (Virtual). **Conceptualization in Treating Infectious Diseases: A Framework to Achieve Optimal Outcomes**

January 2021. 4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference (Virtual). **(Re)focusing Antimicrobial Stewardship Efforts on Improving Patient Outcomes.**

December 2020. American Society of Health-Systems Pharmacists Annual Midyear Meeting (Virtual). **Vancomycin + Piperacillin Tazobactam: Does It Kill Your Kidneys?** Pro/Con Debate with Marc Scheetz, PharmD.

October 2020. ID week 2020 (virtual). **Top Antimicrobial Stewardship Papers of 2020.**

October 2020. World Antimicrobial Resistance (Virtual) Congress. **Role of Pharmacists in the management of new agents: supporting appropriate use and patient access to new agents.**

October 2020. MJH Life Sciences™ Covid-19 Coalition Webinar Series. **Navigating the COVID-19 Treatment Landscape: Clinical Controversies Explained.** Panel discussion with Susan Davis, PharmD and Jason Gallagher, PharmD.

May 2020. Royal Pharmaceutical Society and United Kingdom Clinical Pharmacy Association Webinar. **Clinical Pharmacy, Antimicrobial Stewardship, and Covid-19.** Panel discussion with Erin McCreary, PharmD, Jacqui Sneddon, BSc, MSc, PhD, and Mark Gilchrist MPharm, MSc

November 2019. World Antimicrobial Resistance Congress. Washington DC. **Keynote address: 360 of hospital purchasing and antibiotic use – understanding price-based vs stewardship-based purchasing decisions for new antibiotics & diagnostic.** Panel discussion with Dr. Tom File, MD.

July 2019. Infectious Diseases Association of California Spring Meeting. Oakland. California. **How to Identify Targets, Choose the Correct Metrics to Measure, and Demonstrate Efficacy of Interventions.**

July 2019. Infectious Diseases Association of California Spring Meeting. Oakland. California. **Dose optimization as an antimicrobial stewardship strategy.**

May 2019. 10<sup>th</sup> Annual International Antimicrobial Stewardship Conference sponsored by the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. St. Louis, Missouri. **New and emerging therapies for multi-drug (MDR) and extensively drug resistant (XDR) Gram-negative pathogens.**

March 2019. 3<sup>rd</sup> Annual Three Rivers Antimicrobial Stewardship Symposium. Pittsburgh, PA. **Dose optimization as an antimicrobial stewardship strategy.**

March 2019. 3<sup>rd</sup> Annual Three Rivers Antimicrobial Stewardship Symposium. Pittsburgh, PA. **A steward's guide to Verigene optimization.**

November 2018. Infectious Diseases Association of California Spring Meeting. Grove City, California. **How to Identify Targets, Choose the Correct Metrics to Measure, and Demonstrate Efficacy of Interventions.**

November 2018. Infectious Diseases Association of California Spring Meeting. Grove City, California. **Dose optimization as an antimicrobial stewardship strategy.**

November 2018. Society of Infectious Diseases Pharmacists Education Center (SIDPEC) Webinar Series. **Vancomycin: From Trough to AUC.**

October 2018. American College of Clinical Pharmacists Global Conference on Clinical Pharmacy. Seattle, WA. **Highlights from the Polymyxin Guidelines Part one: Agent selection, dosing recommendations, and strategies to decrease toxicity**

September 2018. United States Committee on Antimicrobial Susceptibility Testing (USCAST) Annual Meeting. Baltimore, MD. **Antimicrobial Stewardship Challenges Raised by Suboptimal Breakpoints.**

July 2018. 1<sup>st</sup> Annual Alabama Infectious Diseases Society (ALIDS) Annual Meeting. Keynote Lecture. **Dose Optimization and an Antimicrobial Stewardship Strategy.**

June 2018. 6<sup>th</sup> Congreso Centroamericano y del Caribe de Infectología. San Jose, Costa Rica. **Know Thy Enemy: Strategies to optimize time to effective therapy.**

May 2018. 21<sup>st</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting; Orlando, FL. **Should Extended Infusion of Beta-Lactams Be the Standard of Care in Hospitals?**

May 2018. 21<sup>st</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting; Orlando, FL. **AUC's: The New TDM.**

December 2017. Nationwide Antibiotic Stewardship in Hospitals Workshop, Tel Aviv, Israel. **Dosing Considerations for Special Populations.**

December 2017. Nationwide Antibiotic Stewardship in Hospitals Workshop, Tel Aviv, Israel. **Designing, Implementing, and Measuring Stewardship Interventions: Guidelines and Pathways.**

November 2017. National Congress of Hospital Pharmacists –10<sup>a</sup> SEMANA APFH, Estonia, Portugal. **Infections due to Multi-drug Resistant Gram-Negative Pathogens: A Challenge and an Opportunity.**

November 2017. National Congress of Hospital Pharmacists –10<sup>a</sup> SEMANA APFH, Estonia, Portugal. **Identifying Stewardship Targets and Measuring Interventions: A Playbook for Clinical Pharmacists.**

October 2017. United States Committee on Antimicrobial Susceptibility Testing (USCAST) Annual Meeting. Baltimore, MD. **Polymyxin (colistin and polymyxin B) breakpoints: Can we get there yet?**

October 2017. American College of Clinical Pharmacists Annual Meeting, Phoenix, AZ. **Real or not real? Vancomycin, Piperacillin/tazobactam, and acute kidney injury (AKI).**

October 2017. American College of Clinical Pharmacists Annual Meeting, Phoenix, AZ. **New and emerging treatment options for multi-drug (MDR) and extensively drug resistant (XDR) Gram-negative pathogens.**

June 2017. ASM Microbe Annual Meeting. New Orleans, LA. **Treatment of infections due to carbapenem-resistant Gram-negative pathogens: Optimal management strategies.**

March 2017. European Association of Hospital Pharmacists Annual Meeting, Cannes, France. **New therapeutic options for the treatment of resistant Gram-negative organisms: A primer.**

December 2016. ASHP Midyear Annual Meeting. **Antimicrobial Stewardship and TJC/CMS: How Did We Get Here?**

October 2016. ID Week. New Orleans, LA. **Which is it? The Great Polymyxin Debate.**

October 2016. Best Practices for Antimicrobial Stewardship Programs workshop at ID week. New Orleans, LA. **When should I recommend extended infusion beta lactams?**

October 2016. American College of Clinical Pharmacy (ACCP) annual meeting, Hollywood, FL. **Clinical controversies in the management of infections due to multidrug-resistant Gram-negative bacilli.**

September 2016. Research symposium at the Institute of Antibiotics, Huashan Hospital, Shanghai, China. Keynote Lecture: **Developing your clinical research path: One man's journey from the USA.**

June 2016. ASM Microbe Annual Meeting. Boston, MA. **Treatment Options for Problematic Gram-negative Pathogens.**

May 2016. 19<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Polymyxin B vs Colistin: One of These Things is Not Like the Other!**

May 2016. 19<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Current Treatment Options for Troublesome Gram-negative Infections**

February 2016. Society of Critical Care Medicine Annual Meeting. Orlando, FL. **New and emerging treatment options for Gram-negative bacilli.**

January 2015. Society of Critical Care Medicine Annual Meeting, Phoenix, AZ. **Treatment options for *Acinetobacter baumannii*.**

October 2014. American College of Clinical Pharmacy annual meeting, Austin, TX. **Updates and challenges in managing drug-resistant Gram-negative pathogens.**

October 2014. ID Week. Philadelphia, PA. **Utilizing the EMR to Enhance Stewardship Efforts.**

May 2014. 17<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **An Update on Polymyxin Use.**

April 2014. 24<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain. **Colistin-associated nephrotoxicity: The impact of definition.**

December 2013. American Society of Health-Systems Pharmacists Annual Midyear Meeting. Orlando, FL. **What's the latest on carbapenem-resistant enterobacteriaceae.**

June 2013. American Society of Health-Systems Pharmacists Summer Meeting. Minneapolis, MN. **Antibiotic sensitivity reactions: clinical implications and management.**

May 2013. 16<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy Annual Meeting. Orlando, FL. **Practical Pharmacokinetics and Pharmacodynamics.**

May 2013. 1<sup>st</sup> International Conference on the Polymyxins. Prato, Italy. **Incidence of and risk factors for colistin and polymyxin B nephrotoxicity in the modern era.**

December 2012. American Society of Health-Systems Pharmacists Annual Midyear Meeting. Las Vegas, NV. **Are carbapenems always the drug of choice for extended spectrum beta-lactamase (ESBL) producers.**

September 2012. Society of Infectious Diseases Pharmacists Annual Meeting. San Francisco, CA. **Combating Gram-negative Resistance.**

April 2012. 22<sup>nd</sup> European Congress of Clinical Microbiology and Infectious Diseases. London, United Kingdom. **The effect of automated alerts on time to appropriate therapy for Gram-negative bacteremia.**

December 2006. American Society of Health-Systems Pharmacists Annual Midyear Meeting. Anaheim, CA. **So, your patient has a “sulfa allergy ...”**

**Selected Local and Regional Presentations:**

March 2026. Memorial Sloan Kettering/ Weill Cornell Infectious Diseases Grand Rounds (virtual). **Exploring Clinical Controversies for the Optimal Treatment of *P. aeruginosa*.**

August 2024. Michigan Pharmacists Association 4th Annual Outpatient Antimicrobial Stewardship Innovations Symposium (OASIS). Grand Rapids, MI. **Outpatient Antibiotic Prescribing for Sinusitis in Michigan: 2019 – 2021.**

October 2023. Trinity Health Ann Arbor Infectious Diseases Grand Rounds. Ann Arbor, MI. **The latest on CP-CRE in Michigan: Epidemiology and Management**

September 2022. Ohio State University College of Pharmacy. **Pushing Infectious Diseases Pharmacotherapy Forward**

February 2022. Michigan Pharmacists Association Annual Meeting. Detroit, MI. **The latest on the prevention and treatment of COVID-19.**

November 2021. Infectious Diseases Grand Rounds, Rutgers University (Virtual). **B-lactam resistance in *P. aeruginosa* and the role of the novel agents.**

September 2021. University of Michigan Library Staff. **COVID-19 Vaccine Q and A.**

June 2021. Infectious Diseases Grand Rounds, Michigan Medicine. **B-lactam resistance in *P. aeruginosa* and the role of the novel agents.**

March 2021. Great Lakes Pharmacy Conference (Virtual). **Antimicrobial Resistance and the ID Pharmacist.**

March 2021. Great Lakes Pharmacy Conference (Virtual). **COVID-19 Therapeutics.**

February 2021. Southeastern Michigan Society of Health System Pharmacists. **COVID-19 Q and A.** Panelist with Susan Davis, PharmD.

September 2020. Michigan Pharmacists Association (virtual) Town Hall. **COVID-19 Lessons Learned.** Panel discussion with Scott Kollmeyer, PharmD.

January 2019. Detroit Medical Center Pharmacy Grand Rounds. Detroit, MI. **Updates from the Antimicrobial Subcommittee.**

January 2018. Detroit Medical Center Pharmacy Grand Rounds. Detroit, MI. **Updates from the Antimicrobial Subcommittee.**

October 2017. 5th Annual Update in Infectious Diseases, Wayne State University School of Medicine, Detroit, MI. **Updates in the Prevention and Management of Seasonal Influenza.**

May 2017. Detroit Medical Center Pharmacy Grand Rounds. Detroit, MI. **Treatment options for Multi-drug (MDR) and Extensively drug resistant (XDR) Gram-negative pathogens: A case-based approach.**

February 2017. The Detroit Medical Center's annual infectious diseases and critical care symposium. Dearborn, MI. **Antimicrobial Stewardship opportunities in commonly encountered infectious diseases.**

December 2015. Tenet Healthcare System Pharmacy Webinar Series. **Antimicrobial Stewardship and the clinical pharmacist: A case-based review.**

July 2015. Wayne State University Annual Update in Internal Medicine, Bay Harbor, MI. **What's new and what's in the pipeline.**

July 2015. Wayne State University Annual Update in Internal Medicine, Bay Harbor, MI. **Prevention and treatment of Seasonal Influenza.**

July 2015. Wayne State University Annual Update in Internal Medicine, Bay Harbor, MI. **We Can Do Better! Antimicrobial Stewardship in Commonly Encountered Infectious Diseases.**

November 2014. Michigan Society of Health System Pharmacists annual meeting, Grand Rapids, MI. **Prevention and treatment of Seasonal Influenza.**

September 2014. Wayne State University's annual "Update in Infectious Diseases", Detroit, MI. **We Can Do Better! Antimicrobial Stewardship in Commonly Encountered Infectious Diseases.**

November 2013. Midwestern University College of Pharmacy annual Clinical Update in Infectious Diseases conference, Chicago, IL. Keynote Lecture: **Carbapenem-resistant Gram-negative bacilli: The past, The present, and The Future.**

September 2012. Fall Meeting of the Southeastern Michigan Society of Health-System Pharmacists (SMSHP). Warren, MI. **Vancomycin versus linezolid for the treatment of MRSA pneumonia: what does the evidence tell us?**

May 2012. Detroit Medical Center Pharmacy Grand Rounds. Detroit, MI. **Clinical controversies in infectious diseases pharmacotherapy: Does the recent evidence change the recommendations?**

November 2011. Michigan Society of Health-System Pharmacists Annual Meeting. Novi, MI. **Colistin dosing: Do we have a clue what we are doing yet?**

January 2011. Detroit Medical Center's 15<sup>th</sup> annual infectious diseases and critical care symposium. Dearborn, MI. **Revisiting old antibiotics in the era of multi-drug resistance.**

January 2011. Detroit Medical Center Pharmacy Grand Rounds. Detroit, MI. **Criteria Monitored Drugs in the DMC: An update.**

May 2010. Sinai-Grace Hospital, Private Physicians LLC (PLLC). Detroit, MI. **The current state and direction of antimicrobial stewardship at Sinai-Grace Hospital.**

November 2009. Wayne State University 5<sup>th</sup> Annual Fall CE Symposium: Emerging Trends in the Treatment of Infectious Diseases, Detroit, MI. **Getting started: Selecting the right targets for intervention.**

January 2008. Pharmacy Grand Rounds. University of Michigan Health Systems. Ann Arbor, MI. **The role of antibiotic prophylaxis in necrotizing pancreatitis.**

November 2007. Pediatric Infectious Diseases Grand Rounds. University of Michigan Health Systems.  
Ann Arbor, MI. **Upcoming antibiotics: coming soon to a pharmacy near you.**

**Book Chapters:**

**Pogue JM**, McCreary EK, Justo JA. Coronavirus disease 2019 (COVID-19). In *Pharmacotherapy: A Pathophysiologic Approach*, 12e. Joseph T. DiPiro, Gary C. Yee, L. Michael Posey, Stuart T. Haines, Thomas D. Nolin, Vicki Ellingrod.

**Pogue, JM** Scheetz, M. (2018). What Every Steward Should Know About Pharmacokinetics and Pharmacodynamics. In T. Barlam, M. Neuhauser, P. Tamma, & K. Trivedi (Eds.), *Practical Implementation of an Antibiotic Stewardship Program* (pp. 155-174). Cambridge: Cambridge University Press.

Kaye KS, **Pogue JM**, Kaye D. "Polymyxins (polymyxin b and colistin)." In *Principles and Practice of Infectious Diseases*, 9th edition, Gerald L. Mandell, John E. Bennett and Raphael Dolin editors, Churchill Livingstone.

**Pogue JM**, Dudley MN, Eranki A, Kaye KS. "Tetracyclines and Chloramphenicol" In *Infectious Diseases*, 4th Edition, Jonathan Cohen, William G Powederly, Steven M. Opal.

**Pogue JM** Tam VH. "Toxicities in Patients." In *Polymyxin Antibiotics: From Laboratory Bench to Bedside*. Jian Li, Roger L. Nation, Keith Kaye.

**Pogue JM**, Ortwine JK, Kaye KS. Optimal use of Gram-negative antibiotics in the real-world: providing effective therapy while minimizing resistance. In *Antibiotic Stewardship: Principles and Practice*.

**Abstracts:**

157. Shields RK, Albrecht B, Abbo LM, Adams J, Argotsinger J, Babiker A, Burgoon R, Chatterji D, DeSear KE, Dorazio AJ, Green SG, Gottesdiner LS, Harrington J, Herald F, Hodgson HA, Hornback KM, Jaffa R, Jeffres MN, Kang AY, Kline EG, Jobic E, Kufel WD, Kunz Coyne AJ, Lee S, Lee L, Lucas K, Marschall J, McCreary EK, Medernach RL, Miller LG, Miller JL, Morrisette T, Potter MH, Rust TT, Satlin MJ, Satola SW, Shah S, Vidal G, Vega AD, Venugopalan V, Wangchinda W, Witt LS, Wu JY, **Pogue JM**. Ceftazidime-Avibactam versus Meropenem-Vaborbactam for the treatment of bloodstream infections and/or pneumonia due to carbapenem-resistant Enterobacterales (CAMEL) (platform presentation). Society of Infectious Diseases Pharmacists (SIDP)/Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Annual Meeting 2026. 14-17 May. Orlando, FL.

156. **Pogue JM**, Abbo LM, Al Shalkhli HA, Argotsinger J, Babiker A, Britt RS, Burgoon R, Claeys KC, Pinargote Comejo P, Dickinso DT, Dorazio AJ, Ereshefsky B, Ferren S, Freiberg J, Golnabi EY, Green KN, Harrington JM, Herald F, Heil EL, Herrington M, Hodgson HA, Hornback KM, Humphries R, Igles D, Kaye KS, Klatt ME, Kline EG, Kobic E, Kubat RC, Kufel WD, Majumdar A, Marschall J, McCreary EK, Merdernach RL, Miller JL, Morrisette T, Potter MH, Shah S, Vu C, Vega AD, VanNatta Day M, Zaidan N, Shields RK. Treatment strategies and clinical outcomes for patients with pneumonia and/or bloodstream infection (BSI) due to Carbapenem-Resistant *A. baumannii* (CRAB): Early insights from the TUNDRA study. Society of Infectious Diseases Pharmacists (SIDP)/Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Annual Meeting 2026. 14-17 May. Orlando, FL.

155. Harrington JM, Rodriguez D, Aitken SL, Arnold P, Eschenauer G, Gandhi T, Green K, Hensler D, Ingebrigtsen M, Kenes M, Miller JT, Nagel JL, Wangchinda W, Zimmerman C, **Pogue JM**. Implementation of a Novel Risk Factor-based Algorithm for Empiric Gram-Negative Treatment of Pneumonia in the Intensive Care Unit. Society of Infectious Diseases Pharmacists (SIDP)/Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Annual Meeting 2026. 14-17 May. Orlando, FL.

154. Green KN, Nagel J, **Pogue JM**. Optimization of Empiric Therapy for UTIs with Urinary Antibiograms

Stratified by Patient Specific Factors. Society of Infectious Diseases Pharmacists (SIDP)/Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Annual Meeting 2026. 14-17 May. Orlando, FL.

153. Patauner F, Seok H, Narayanan N, **Pogue JM**, Durante-Mangoni E, Kaye KS. Gram-negative Randomized Controlled Trials (RCTs) in the 21st Century: Characteristics and Evolution. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global. 17-21 April. Munich, Germany.

152. Lavoie T, **Pogue JM**. Genomic characterization of treatment-emergent blaKPC-3 variants under simulated pulmonary ceftazidime-avibactam exposure. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global. 17-21 April. Munich, Germany.

151. **Pogue JM**, Adams J, Anderson E, Babiker A, Ereshefsky B, Freiberg J, Harrington J, Herald F, Hobbs ALV, Hodgson H, Humphries R, Klatt ME, Kline EG, Kubat RC, Kufel WD, McCreary EM, Medernach R, Miller WR, Pearson JC, Sheckelhoff T, Shah S, Tran TT, Tran NN, Vissichelli NC, Wu JY, Kobir E, Potter MH, Wangchinda W, Shields RK. Cefiderocol treatment versus ceftolozane/tazobactam for the treatment of pneumonia and/or bloodstream infections due to multidrug-resistant *Pseudomonas aeruginosa* (CONVINCE). European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global. 17-21 April. Munich, Germany.

150. Vasco K, McNamara S, Miles-Jay A, Jones K, McCullor K, Soehnen M, Brennan B, Blankenship H, **Pogue JM**. Emergence and genomic context of aztreonam-avibactam non-susceptibility in metallo- $\beta$ -lactamase-producing *Escherichia coli* in Michigan. Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) 2026. 28 – 30 January. Las Vegas, NV.

149. **Pogue JM**, Adams J, Albrecht B, Colven R, Van Natta Day M, DeSear K, Dickson DT, Ereshefsky B, Freiberg JA, Gallagher JC, Gohnabi E, Heil EL, Herald F, Hobbs ALV, Jaffa R, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee HS, Lepak AJ, MacDougall C, Moore WJ, Pham CU, Pinargote P, Sassine J, Satlin MJ, Tran N, van Duin D, Vega A, Venugopalan V, Veve MP, White B, Witt LS, Wu JY, Zaidan N, Shields RK. Preferred management strategies for Carbapenem-Resistant *A. baumannii* (CRAB) in the United States: Insights from the PRECEDENT Network. Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) 2026. 28 – 30 January. Las Vegas, NV.

148. Wangchinda W, **Pogue JM**, Abbo LM, Klatt M, Kline EG, Kubat R, Gilboa M, Vega A, Zhou Y, Yucel E, Shields RK. Effectiveness of imipenem-Relebactam for multidrug-resistant *Pseudomonas Aeruginosa* in pneumonia and bloodstream infections in the United States (MIRAGE). ID week 2025, 19-22 October, Atlanta, GA.

147. Frazer A, Stier E, Haddad A, Degala S, Brennan B, Scott A, Malani A, **Pogue JM**. Antibiotic Prescribing Patterns among Outpatients with Acute Cystitis in Michigan. ID week 2025, 19-22 October, Atlanta, GA.

146. Harrington J, Nagel J, Sallerson S, Yan X, Aitken SL, Marshall V, Pai M, Lawless B, **Pogue JM**, Eschenauer G. Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting. ID week 2025, 19-22 October, Atlanta, GA.

145. **Pogue JM**, Kaye KS, Wagenaar R, Rodriguez M, Steenbergen JN. Assessment of the fosfomycin 200  $\mu$ g disk diffusion against resistant Enterobacterales: data from the intravenous fosfomycin (IV-FOS) clinical trial program for complicated urinary tract infection program. ID week 2025, 19-22 October, Atlanta, GA.

144. Wangchinda W, **Pogue JM**, Abbo LM, Klatt M, Kline EG, Kubat R, Gilboa M, Vega A, Zhou Y, Yucel E, Shields RK. Effectiveness of imipenem-Relebactam for multidrug-resistant *Pseudomonas Aeruginosa* in pneumonia and bloodstream infections in the United States (MIRAGE): Preliminary Results. ID week 2024, 16 – 19 October. Los Angeles, CA.

143. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JG, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JH, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxe J, Pearson J, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma PD, Vega A, Venugopalan V, Veve M, Wangchinda W, Witt LS, Wu J, **Pogue JM**. Impact of patient subgroups on the efficacy of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS) (platform presentation). ID week 2024, 16 – 19 October. Los Angeles, CA

142. **Pogue JM**, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JG, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JH, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxe J, Pearson J, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma PD, Vega A, Venugopalan V, Veve M, Wangchinda W, Witt LS, Wu J, Shields RK. Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (platform presentation). ID week 2024, 16 – 19 October. Los Angeles, CA

141. Lavoie T, Daffinee K, **Pogue JM**, Achour B, LaPlante K. Unlocking Potentials: The Impact of Meropenem, Meropenem-vaborbactam, and Ceftazidime-avibactam in Combatting Carbapenem-resistant *Enterobacter cloacae* in Epithelial Lining Fluid and Serum. ID week 2024, 16 – 19 October. Los Angeles, CA.

140. Wangchinda W, Haddad A, Stier E, Brennan BM, Malani AN, Lo L, **Pogue JM**. Antibiotic Prescribing Patterns among Outpatients with Acute Sinusitis in Michigan. ID week 2024, 16 – 19 October. Los Angeles, CA.

139. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JG, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JH, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxe J, Pearson J, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma PD, Vega A, Venugopalan V, Veve M, Wangchinda W, Witt LS, Wu J, **Pogue JM**. Efficacy of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS) among immunocompromised patients. 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain

138. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JG, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JH, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxe J, Pearson J, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma PD, Vega A, Venugopalan V, Veve M, Wangchinda W, Witt LS, Wu J, **Pogue JM**. Time to clinical response among patients treated with Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS). 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain [Platform presentation].

137. Lavoie T, Daffinee K, **Pogue JM**, Achour B, LaPlante K. Humanized serum concentrations of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam against carbapenem-resistant *Enterobacter cloacae*. 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain

136. Huralaska M, **Pogue JM**, Sheikh H, Rybak MJ, Ghazaryan V, Kaye KS. Colistin Plus Meropenem: The Impact of Synergy on Outcomes in the OVERCOME Trial. 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain

135. **Pogue JM**, Rybak MJ, Narayanan N, Ghazyaran V, Kaye KS. Impact of colistin MIC on outcomes: Results from the OVERCOME Trial comparing colistin monotherapy and colistin + meropenem combination therapy. 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain
134. Jenkins A, Gillian S, Hussain S, Hughes S, Ashton C, Hamilton RA, Khadem TM, Yakemowicz C, **Pogue JM**, McCreary EK. Jabs to Tabs Goes Global: Point-Prevalence of Doses of Intravenous Antibiotic Administered as a Function of Daily Census. 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain
133. Kaye KS, **Pogue JM**, Dennison J, Perry C, Huang C, Luck ME, Mulgirigama A, Janmohamed S, Sheets AJ. Early symptom response in patients with uncomplicated urinary tract infection treated with gepotidacin or nitrofurantoin: pooled data from two pivotal phase 3 studies. 34th European Congress of Clinical Microbiology and Infectious Diseases. 27 - 30 April 2024, Barcelona, Spain
132. Wangchinda W, Aitken SL, Lephart PR, **Pogue JM**. Stratification of Patient-Specific Risk Factors for Multidrug-Resistant Gram-Negative Respiratory Pathogens in Intensive Care Units (ICU). IDWeek 2023, October 11-15, Boston MA
131. Wangchinda W, Aitken SL, Lephart PR, **Pogue JM**. A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) Caused by Gram-Negative Bacteria in Intensive Care Units (ICU). IDWeek 2023, October 11-15, Boston MA
130. Wangchinda W, Aitken SL, Pierce VM, Lephart PR, **Pogue JM**. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates. IDWeek 2023, October 11-15, Boston MA
129. Wangchinda W, **Pogue JM**, Thamlikitul V, Leelawattanachai P, Koomanachai P, Pai M. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections. IDWeek 2023, October 11-15, Boston MA. [Platform presentation]
128. Lee M, Nigel J, Wangchinda W, Pierce VM, Bishop O, **Pogue JM**. Risk Factors for Infection or Colonization with Ceftolozane/Tazobactam Non-Susceptible Extensively  $\beta$ -Lactam Resistant *Pseudomonas aeruginosa*. IDWeek 2023, October 11-15, Boston MA
127. Brennan B, McNamara S, Stier E, Malani AN, **Pogue JM**, Ressler A, Eckel S, Coyle J, Bagdasarian N. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of *Candida auris*: The Michigan Experience. IDWeek 2023, October 11-15, Boston MA
126. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JG, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JH, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxe J, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma PD, Vega A, Venugopalan V, Veve M, Wangchinda W, Witt LS, Wu J, **Pogue JM**. A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS). IDWeek 2023, October 11-15, Boston MA. [Platform presentation]
125. Lavoie T, Daffinee K, **Pogue JM**, Achour B, Laplante K: Comparing Efficacy of Serum and Epithelial Lining Fluid Concentrations for Meropenem Against Carbapenem-Resistant Enterobacterales. Selected for poster presentation at IDWeek 2023, October 11-15, Boston MA.

124. Wangchinda W, Kaye KS, Patel TS, Albin A, Saravolatz L, **Pogue JM**. Risk Prediction Tools for Drug-Resistant *Pseudomonas aeruginosa*. Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Annual Meeting 2023. Orlando, FL.

123. Vita AJ, Rice S, Albin O, Patel TS, Styron CN, Kaye KS, **Pogue JM**. Risk Factors for Infection or Colonization with Piperacillin-Tazobactam (TZP) Resistant *P. aeruginosa* with increasing degrees of  $\beta$ -lactam Resistance. ID Week 2022. Washington D.C.

122. Gupta V, Yu KC, **Pogue JM**, Watts J, Clancy CJ. Trends in carbapenem non-susceptible (Carb-NS) Enterobacterales from hospitalized patients in the US from 2014-2020: A comparison between organisms with and without concerns for chromosomal AmpC beta-lactamase hyperproduction. ID week 2022. Washington D.C.

121. Naas T, **Pogue JM**, Kaye KS, Baba T, Menon A, Echols R, Yamano Y, Longshaw C, Portsmouth S. Efficacy of Cefiderocol in Patients with Nosocomial Pneumonia and Complicated Urinary Tract Infections Caused by Enterobacterales and Carbapenem-Resistant Enterobacterales (CREs) from Three Randomised Clinical Trials. ECCMID 2022. Lisbon, Portugal.

120. Rao K, Zhao Q, Bell J, Krishnan J, Henig O, Daniel J, Sawaya K, Albin O, Mills J, Petty L, Gregg K, Kaul D, Malani A, **Pogue JM**, Kaye KS. Comparison of fidaxomicin and oral vancomycin for the treatment of *Clostridioides difficile* infection in hospitalized patients receiving concomitant antibiotics for concurrent infections. SHEA Spring Meeting 2022, Atlanta, GA.

119. Gupta V, Yu K, **Pogue JM**, Watts J, Clancy CJ. Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem not-susceptible (Carb-NS) *Pseudomonas aeruginosa* (PSA) from 2016-2019: A multicenter evaluation. ID week 2021 (virtual)

118. Gupta V, Yu K, **Pogue JM**, Watts J, Clancy CJ. Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2020: A multicenter evaluation. ID week 2021 (virtual)

117. Kalaria S, **Pogue JM**, Heil E. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients. ID week 2021 (virtual).

116. **Pogue JM**, Marchaim D, Thamlikitkul T, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Leibovici L, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Divine G, Ghazaryan V, Chiou C, Kaye KS. The Impact of in vitro Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-resistant Gram-negative Infections: A Report from the OVERCOME Trial

115. **Pogue JM**, Marchaim D, Thamlikitkul T, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Leibovici L, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Divine G, Ghazaryan V, Chiou C, Kaye KS. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. ID week 2021 (virtual).

114. Kaye KS, Marchaim D, Thamlikitkul T, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Leibovici L, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Divine G, Ghazaryan V, Chiou C, **Pogue JM**. cOlistin Monotherapy VERsus COMbination Therapy (OVERCOME), NCT01597973, NIH study 10-0065 (platform presentation). ECCMID 2021 (virtual).

113. Klatt M, Dillman N, Eschenauer G, Gandhi T, Marshall V, Nagel J, Patel T, Petty L, Smith A, **Pogue JM**. Comparative in vitro activity of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and cefiderocol against *P. aeruginosa*, including drug-resistant isolates at an academic medical center. ECCMID 2021 (virtual).
112. Klatt M, Dillman N, Eschenauer G, Gandhi T, Marshall V, Nagel J, Patel T, Petty L, Smith A, **Pogue JM**. Rethinking optimization of empiric gram-negative therapy for pneumonia in intensive care units: We can do better. ECCMID 2021 (virtual).
111. Marcella S, Kanakamedala H, Zhou Y, Cai B, **Pogue JM**. Trends of Carbapenem Resistance in Enterobacteriales in the US Between 2015 and 2019. ID Week 2020 (virtual).
110. Patel TS, Kaye KS, Marshall V, Krishnan J, Mills J, Albin O, Smith A, Young C, Lephart P, **Pogue JM**. In vitro Activity of Ceftazidime/Avibactam Compared to Ceftolozane/Tazobactam Against Real World Isolates of *Pseudomonas aeruginosa* at a Large Academic Tertiary Care Hospital. ID Week 2019. Washington DC.
109. Gandhi TN, Petty LA, Vaughn VM, Patel TS, Ratz D, McLaughlin E, Malani AN, Dumkow LE, **Pogue JM**, Thyagarajan R, Hsaiky L, Bernstein SJ, Flanders SA. Assessment of Fluoroquinolone Appropriateness for Hospitalized Patients with Asymptomatic Bacteriuria and Cystitis: A Multi-Hospital Cohort Study. ID Week 2019. Washington DC.
108. **Pogue JM**, Kanakamedala H, Zhou Y, Cai B. Burden of Illness in Carbapenem-resistant *Acinetobacter baumannii* infections in US Hospitals (2014-2018). ID Week 2019. Washington DC.
107. Tran KN, Mynatt RP, Kaye KS, **Pogue JM**. Clinical Outcomes with Extended Infusion (EI) versus Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia. ID Week 2019. Washington DC.
106. Jorgensen SCJ, Trinh TD, Zasowski EJ, Alosaimy S, Melvin S, Dhar S, Mynatt RP, **Pogue JM**, Rybak MJ. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. ID Week 2019. Washington DC.
105. Patel TS, Kaye KS, Krishnan J, Marshall V, Mills J, Albin O, Young C, Smith A, Lephart P, **Pogue JM**. Comparative *In Vitro* Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of *Pseudomonas aeruginosa*. ID Week 2019. Washington DC.
104. Sandhu A, Goldman E, Polistico J, Polistico S, Oudeif A, Aranha A, Murray KP, Zhao J, Mynatt RP, **Pogue JM**, Dhar S. Factors Influencing the Duration of Antimicrobial Therapy for Community Acquired Pneumonia. ID Week 2019. Washington DC.
103. Albin O, Patel TS, Henig O, Valley T, **Pogue JM**, Petty LA, Mills J, Brancaccio A, Kaye KS. Impact of Empiric Aminoglycoside Usage on Outcomes in Bacterial Pneumonia. ID week 2019. Washington DC.
102. Sandhu A, Goldman E, Polistico J, Polistico S, Oudeif A, Aranha A, Murray KP, Zhao J, Mynatt RP, **Pogue JM**, Dhar S. Impact of Utilizing Drug Resistance in Pneumonia (DRIP) Score on Management of Pneumonia. ID Week 2019. Washington DC.
101. Alosaimy S, Jorgensen SCJ, Lagnf A, Zasowski E, Trinh TD, Mynatt RP, **Pogue JM**, Rybak MJ. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI). ID Week 2019. Washington DC.

100. **Pogue JM**, Jones RN, Bradley JS, Andes D, Bhavnani SM, Dudley M, Flamm RK, Rodvold KA, Ambrose PG. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for *P. aeruginosa*, *A. baumannii*, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). ID Week 2019. Washington DC.
99. Petty LA, Vaughn V, Patel TS, Malani AN, **Pogue JM**, Dumkow LE, Thyagarajan R, Hsaiky L, Osterholzer D, Kaye KS, Ratz D, McLaughlin E, Flanders SA, Gandhi TN. Risk Factors Associated with Treatment of Asymptomatic Bacteriuria in the Emergency Department: A Multi-Hospital Cohort Study. ID Week 2019. Washington DC.
98. Simpson T, Shah S, **Pogue JM**, Wu J. Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity. ID Week 2019. Washington DC.
97. Patel TS, Marshall V, Kaye KS, Smith A, Young C, Lephart P, **Pogue JM**. Susceptibility of Beta-Lactam-Resistant *P. aeruginosa* to Other Beta-lactams: Is There Truly a Lack of Cross-Resistance? ID Week 2019. Washington DC.
96. Albin O, Patel TS, Henig O, Mills JP, **Pogue JM**, Petty LA, Valley T, Kaye KS. Clinical Implications of treatment failure in pneumonia: the pathogen matters. ECCMID 2019. Amsterdam, The Netherlands.
95. **Pogue JM**, Marshall V, Smith A, Young C, Lephart P, Kaye KS, Patel TS. Do we have any clue what we are doing to optimize empiric therapy? The *Pseudomonas aeruginosa* example. ECCMID 2019. Amsterdam, The Netherlands.
94. **Pogue JM**, Taylor M, Mynatt RP, Mitchell R, Dhar S, Salimnia H. Comparative activity of plazomicin and conventional aminoglycosides using current CLSI/EUCAST and proposed USCAST breakpoints against carbapenem-resistant Enterobacteriaceae in Detroit, Michigan. ECCMID 2019. Amsterdam, The Netherlands.

93. **Pogue JM**, Kaye KS, Veve MP, Gerlach A, Patel TS, Davis SL, Chaung E, Ray A, Puzniak L, Bonomo RA, Perez F. "Real World" Treatment of Multi-drug Resistant (MDR) or Extensively-drug Resistant (XDR) *P. aeruginosa* Infections with Ceftolozane/Tazobactam (C/T) versus a Polymyxin or Aminoglycoside (Poly/AG) based regimen: A Multicenter Comparative Effectiveness Study. ID Week 2018. San Francisco, CA.
92. Cooper C, Henig O, Kaye KS, Hussain N, Hussain Z, Deeds K, Salimnia H, Lephart P, Hayat U, Patel J, **Pogue JM**. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program & Rapid Genotypic Organism/Resistance Marker Identification. ID Week 2018. San Francisco, CA.
91. Albin O, Henig O, Patel TS, **Pogue JM**, Petty L, Valley T, Mills JP, Kaye KS. Clinical Significance of Microbiologic Treatment Failure following Clinical Cure of Pneumonia. ID Week 2018. San Francisco, CA.
90. Veve MP, **Pogue JM**, Zervos MJ, Davis SL. Treatment Characteristics and Predictors of Mortality in Patients with Infected Chronic Pressure Ulcers in Detroit. ID Week 2018. San Francisco, CA.
89. Parsons L, **Pogue JM**, Lephart P, Boikov D, Kaye KS, Dhar S. Comparison of minocycline MIC's obtained by Etest to those obtained by broth microdilution in a bank of isolates of *Acinetobacter baumannii* collected in Southeastern Michigan. ID week 2018. San Francisco, CA.
88. Cwengros LN, Mynatt RP, Timbrook TT, **Pogue JM**. Minimizing Time to Optimal Therapy for Enterobacteriaceae Bloodstream Infections: Is Organism Identification Enough? ID Week 2018. San Francisco, CA.
87. Onufrak NJ, Bhavnani SM, **Pogue JM**, Rubino CM. Evaluating the Dissonance between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against *Pseudomonas aeruginosa* (PA) as a Case Study. ID week 2018. San Francisco, CA.
86. **Pogue JM**, Sanagaram R, Merchant S, Taina P, Puzniak L. Real World Clinical Experience with Ceftolozane/Tazobactam (C/T) for the Treatment of Complicated Urinary Tract Infection (cUTI) and Intra-abdominal Infection (cIAI) due to *Pseudomonas aeruginosa* (PSA): An Electronic Medical Record (EMR) database review in the United States (US). ECCMID 2018. Madrid, Spain
85. Smith NM, Lakota EA, Lenhard JR, Bulitta JB, Mergenhagen KA, **Pogue JM**, Kaye KS, Nation RL, Li J, Forrest A, Tsuji BT. Translating Polymyxin B and Meropenem Synergy against Carbapenem-Resistant *Acinetobacter baumannii*: Moving Toward a Rational, Combinatorial Pharmacokinetic Target. ECCMID 2018. Madrid, Spain
84. Patel TS, Kaye KS, Mills JP, Lephart P, Bachman M, Smith A, Marshall V, **Pogue JM**. In Vitro Antimicrobial Activity of Ceftolozane/tazobactam Against Real World Clinical Isolates of Non-fermenting Gram-negative Bacilli at a Large Academic Tertiary Care Hospital. ECCMID 2018. Madrid, Spain.
83. Cwengros LN, Tran K, Mynatt RP, Kaye KS, **Pogue JM**. Sulfamethoxazole/trimethoprim associated acute kidney injury: Real or a mirage? ECCMID 2018. Madrid, Spain
82. **Pogue JM**, Lephart P, Mitchell R, Fairfax M, Salimnia H. Comparative activity of meropenem/vaborbactam (MV) and ceftazidime/avibactam (CA) against carbapenem-resistant

Enterobacteriaceae (CRE) isolated from clinical specimens at the Detroit Medical Center (DMC). ECCMID 2018. Madrid, Spain.

81. Wu J, Mynatt RP, Kaye KS, **Pogue JM**. Risk Factors for Colonization or Infection with Cefepime Resistant, Piperacillin-Tazobactam Susceptible Gram-Negative Bacilli. ID Week 2017. San Diego, CA.

80. **Pogue JM**, Puzniak L, Merchant S, Sanagram R, Rhee E. Real World Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States. ID Week 2017. San Diego, CA.

79. Claeys K, **Pogue JM**, Lephart P, Heil E, Johnson JK. Gram-Negative Polymicrobial Bloodstream Infections and Clinical Decision Making with a Microarray Testing System. ID Week 2017. San Diego, CA.

78. Flynt LK, Jenney RM, Veve M, **Pogue JM**, Abreu-Lanfranco O, Davis SL. Optimized Beta-Lactam Therapy Improves Survival in Carbapenem Non-Susceptible Gram-Negative Infections. ID week 2017. San Diego, CA.

77. Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Dhar S, Mynatt RP, **Pogue JM**, Rybak MJ. Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI). ID Week 2017. San Diego, CA.

76. Singh S, Menon V, Kumar A, Nampoothiri V, Mohamed ZU, Sudhir S, **Pogue JM**, Kaye KS. Implementation of Antibiotic stewardship: A South Indian experience. ID week 2017. San Diego, CA.

75. McKinnell JA, Connoly LE, Pushkin R, Jubb AM, O'Keeffe B, Serio AW, Smith A, Gall J, Riddle V, Krause KM, **Pogue JM**. Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study. ID Week 2017, San Diego, CA.

74. Menon V, Patel P, Nampoothiri V, Kumar A, Umer Mohamed Z, Sudhir S, **Pogue JM**, Singh S, Kaye KS. Epidemiology of Polymyxin use in a tertiary care setting of South India. ID Week 2017, San Diego, CA.

73. Henig O, **Pogue JM**, Cha R, Dhar S, Hayat U, Ja'Ara M, Kilgore PE, Kaye KS. High Rates of Multidrug Resistance in Diabetic Foot Infection in Detroit Area: Does It Matter? ID Week 2017, San Diego, CA.

72. Henig O, **Pogue JM**, Cha R, Kilgore P, Ja'ara M, Hayat U, Mahboob S, Raza M, Kaye KS. Associations between Different Antimicrobials and Specific Multidrug Resistant Organisms in Diabetic Foot Infection (DFI-MDRO) in Detroit Medical Center. ASM Microbe 2017, New Orleans, LA.

71. Kaye KS, Darouiche R, File T, **Pogue JM**, Dudley MN, Loutit J. Meropenem-Vaborbactam (M-V): Clinical Outcomes by Bacteremia Status in a Phase 3 Randomized, Double-blind Trial in cUTIs (TANGO 1). ASM Microbe 2017, New Orleans, LA.

70. **Pogue JM**, Merchant S, Rhee EG, Puzniak L, Motyl M, Murray J, Caldwell L, and Gupta V. Susceptibility of ceftolozane/tazobactam (C/T) to multi drug resistant (MDR) *Pseudomonas aeruginosa* (PSA) clinical isolates in hospitalized patients: A multicenter evaluation. ASM Microbe 2017, New Orleans, LA.

69. Navalkele B, **Pogue JM**, Nishan B, Salim M, Koons J, Hussain T, Perry W, Modar A, Abusaaman M, Shivaana S, Shamim M, Kaye KS. Comparison of Treatment Outcomes between Ertapenem and Meropenem in *Enterobacter* species Bloodstream Infections. ASM Microbe 2017, New Orleans, LA.
68. Claeys K, Heil E, Johnson JK, Lephart P, Mynatt RP, Salimnia H, **Pogue JM**. An antibiotic stewardship programme (ASP) blueprint for optimizing Verigene BC-GN within an institution: a tale of two cities. ECCMID 2017. Vienna, Austria.
67. **Pogue JM**, Merchant S, Puzniak L, Hawkshead JJ, Rhee E, Murray J, Gupta V. Ceftolozane/tazobactam prescribing patterns in hospitalized patients: A multicenter evaluation. ECCMID 2017. Vienna, Austria.
66. Zasowski E, Murray K, Trinh T, Finch N, **Pogue JM**, Mynatt R, Rybak MJ. Identification of vancomycin area under the curve toxicity thresholds in hospitalized patients. ECCMID 2017. Vienna, Austria.
65. Lephart P, Kaye KS, **Pogue JM**, Painter T, Burger T, Tayler M, Cooper C, Salimnia H. Evaluation of the Accelerate Pheno™ system in a clinical setting: comparison of identification and antibiotic susceptibility test results of 224 prospective blood cultures to standard laboratory methods at Detroit Medical Center. ECCMID 2017. Vienna, Austria
64. Finch NA, Murray KP, Zasowski E, Mynatt RP, Yost RJ, Zhao JJ, **Pogue JM**, Rybak MJ. Impact of area under the curve (AUC)-targeted dosing on vancomycin-associated nephrotoxicity. ASM Microbe 2016. Boston, MA
63. Navalkele B, **Pogue JM**, Karino S, Rybak MJ, Mynatt RP, Murray K, et.al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/tazobactam Compared to Vancomycin and Cefepime. ASM Microbe 2016. Boston, MA
62. Navalkele B, Karino S, Tashtoush N, Nishan B, Salim M, Pervaiz A, Shaikh H, Ali A, Koppula S, Kaye KS, **Pogue JM**. Acute Kidney Injury in patients on concomitant vancomycin with piperacillin-tazobactam: Are extended infusions to blame? ID week 2015. San Diego, CA.
61. Tashtoush N, **Pogue JM**, Nishan B, Salem D, Shaikh H, Salim M, Pervaiz A, Karino S, Dhar S, Kaye KS. Differentiating Patients with Multi-Drug Resistant (MDR) Gram-Negative Infections Present at the Time of Hospital Admission (POA) From Those with Susceptible (S) and Extremely-Drug Resistant (XDR) Pathogens. ID week 2015. San Diego, CA.
60. Molloy L, **Pogue JM**, Alsagahyer A, Salim M, Nishan B, Shaikh H, Medegoedra N, Kaye KS. Epidemiology and Management of Complicated Urinary Tract Infections (cUTI) in Hospitalized Adults: Opportunities for Carbapenem Stewardship. ID week 2015. San Diego, CA.
59. **Pogue JM**, Karino S, Navalkele B, Martin ET, Tashtoush N, Nishan B, Salim M, Solanki S, Pervaiz A, Shaikh H, Ali A, Koppula S, Mynatt RP, Murray K, Kaye KS. Risk factors for acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam. ID week 2015. San Diego, CA.
58. Roberts K, Mynatt RP, Kaye KS, Murray K, Rybak MJ, Otremba S, Pangrazzi M, **Pogue JM**. Vancomycin associated nephrotoxicity: Is it truly the vancomycin? ICAAC 2015. San Diego, CA.

57. Mynatt RP, Karino S, Tashtoush N, Koppula S, Solanki S, Salim M, Shaikh H, Pervaiz A, Kaye KS, **Pogue JM**. The Chicken or the Egg: Vancomycin Troughs Prior to Acute Kidney Injury are Not Associated with Increased Risk of Nephrotoxicity. ICAAC 2015. San Diego, CA.
56. **Pogue JM**, Mudegowdra N, Balakrishnan G, Salim M, Nisham B, Pervaiz A, Navalkele B, Shaikh H, Kaye KS. Lack of Association between colistin loading dose and acute kidney injury. ICAAC 2015. San Diego, CA.
55. **Pogue JM**, Mudegowdra N, Balakrishnan G, Salim M, Nisham B, Pervaiz A, Navalkele B, Shaikh H, Kaye KS. Lack of Association between colistin loading dose and acute kidney injury [platform presentation]. 2nd international conference on the polymyxins. San Diego, CA.
54. Martin ET, Awasthy P, Marchaim D, **Pogue JM**, Hayakawa K, Kaye KS. High prevalence of ST131 among ESBL producing E coli in the metropolitan Detroit area. [platform presentation]. ECCMID 2015. Copenhagen, Denmark.
53. **Pogue JM**, Martin ET, Kaye KS, Marchaim D, Hayakawa K. Discordance in reported rates of nephrotoxicity associated with colistin: A systematic review to analyze the role of dose and definition. ECCMID 2015. Copenhagen, Denmark.
52. Sutton J, Mynatt RP, Kaye KS, Murray K, Rybak MJ, **Pogue JM**. Nephrotoxicity (NTX) comparison in two commercially available generic vancomycin (VAN) products. ICAAC 2014. Washington, DC
51. Nagel J, **Pogue JM**, Claeys K, Casapao A, Finks J, Neuhauser M, Schneider A, Davis S, Rybak MJ. Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) Antimicrobial Use and Resistance Module (CDC AUR) to Compare Multicenter Antimicrobial Use. ICAAC 2014. Washington, DC.
50. Claeys KC, Nagel J, **Pogue JM**, Casapao AM, Finks J, Neuhauser M, Schneider A, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's (NHSN's) Antimicrobial Use Option to Aid in Determination of Resistance Among Key Nosocomial Pathogens. ICAAC 2014. Washington, DC.
49. **Pogue JM**, Marchaim D, Hayakawa K, Pulluru H, Kaye KS. Colistin-associated nephrotoxicity: The impact of definition. [Platform presentation]. ECCMID 2014. Barcelona, Spain
48. Casapao A, Davis SL, Barr V, Goff D, Kaye KS, **Pogue JM**, Rybak MJ. Retrospective multi-centre experience of the effectiveness and safety with ceftaroline fosamil (CPT) therapy in patients with acute bacterial skin and skin structure infections (ABSSSI). ECCMID 2014. Barcelona, Spain.
47. Casapao A, Davis SL, Barr V, Klinker K, Goff D, Barber KE, Mynatt RP, Kaye KS, **Pogue JM**, Rybak MJ. The effectiveness and safety with ceftaroline fosamil (CPT) therapy for lower respiratory tract infections (LRTI) in a retrospective multi-centre study. ECCMID 2014. Barcelona, Spain.
46. Claeys K, Casapao A, **Pogue JM**, Saely S, Giuliano C, Hafeez W, Kaye K.S, Levine D, Davis SL, Rybak MJ. Rapid diagnostic testing with GeneXpert improves enrolment in a randomised clinical trial for detection of methicillin-resistant *S. aureus* in acute bacterial skin and skin structure infections. ECCMID 2014. Barcelona, Spain.

45. Otremba SA, Chopra T, Awali R, Mynatt RP, Kaye K, **Pogue JM**. The impact of oral vancomycin dose on outcomes for the treatment of severe *Clostridium difficile* infection. Society of Critical Care Medicine 2014. San Francisco, CA.
44. Casapao, AM, Davis, SL, Barr, VO, Klinker, KP, Goff DA, Barber, KE, Steinke, LM, Mynatt, RP, Kaye KS, **Pogue, JM**, Rybak, MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. ICAAC 2013. Denver, CO.
43. Archer C, Evans R, Davis SL, **Pogue JM**, Rybak MJ, Kaye KS, Martin ET. Decreasing MRSA Prevalence Among ABSSSI-associated Hospitalizations in The Detroit Metropolitan Area, 2006-2012. ICAAC 2013. Denver, CO.
42. **Pogue JM**, Hayakawa K, Francis J, Pulluru H, Marchaim D, Kaye KS. Risk factors for and incidence of nephrotoxicity associated with colistin (COL) and polymyxin B (PB) use in the modern era: a comparison [platform presentation]. 1st International Conference on the Polymyxins 2013. Prato, Italy.
41. **Pogue JM**, Kaye KS. Comparative Nephrotoxicity with Colistin Therapy Between Older and Younger Adults: A Propensity Score Analysis. 1st International Conference on the Polymyxins 2013. Prato, Italy.
40. **Pogue JM**, Lephart P, Mynatt RP, Cumby D, Zurack M, Kaye KS. *In vitro* activity of ceftaroline against *Klebsiella* spp. as evaluated by both Broth Microdilution (BMD) and Etest. ECCMID 2013. Berlin, Germany.
39. **Pogue JM**, Kaye KS. Comparative Nephrotoxicity with Colistin Therapy Between Older and Younger Adults: A Propensity Score Analysis. ECCMID 2013. Berlin, Germany.
38. Barber KE, **Pogue JM**, Casapao AM, Rybak MJ. Outcomes Associated with Vancomycin-Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). ICAAC 2012. San Francisco, CA.
37. Hayakawa K, Marchaim D, Bhargava A, Palla M, Alshabani K, Mahesh U, Pulluru H, Bathina P, Sundaragiri PR, Sarkar M, Kakarlapudi H, Ramasamy B, Nanjireddy P, Mohin S, Dasagi M, Datla S, Kuchipudi V, Reddy S, Shahani S, Upputuri V, Moshos JA, Lephart PR, Martin ET, Flanagan E, **Pogue JM**, Kaye KS. Current epidemiology and clinical impact of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* at a tertiary medical center. APIC 2012. San Antonio, TX.
36. Palla M, Hayakawa K, Marchaim D, Mahesh U, Pulluru H, Lee KP, Kamatam S, Manit S, Ajamoughli M, Bathina P, Alshabani K, Govindavarjhulla A, Mallad A, Ho K, Abbadi DR, Chowdary D, Kakarlapudi H, Guddati H, Das M, Kannekanti N, Ramasamy B, Khan A, Vemuri P, Doddamani R, Rakesh Mundra VR, Guddeti RR, Policherla R, Bai S, Lohithaswa S, Shashidharan SP, Chidurala S, Diviti S, Patel D, Vadlamudi G, Obeid T, **Pogue JM**, Lephart PR, Martin ET, Flanagan E, Rybak MJ, Kaye KS. Risk factors for the isolation of Vancomycin-resistant *Enterococcus faecalis* from wound site: A case-case control analysis. APIC 2012. San Antonio, TX.
35. Hayakawa K, Marchaim D, Palla M, Mahesh U, Pulluru H, Lee KP, Kamatam S, Singla M, Ajamoughli M, Bathina P, Alshabani K, Govindavarjhulla A, Mallad A, Ho K, Abbadi DR, Chowdary D, Kakarlapudi H, Guddati H, Das M, Kannekanti N, Ramasamy B, Khan A, Vemuri P, Doddamani R, Rakesh Mundra VR, Guddeti RR, Policherla R, Bai S, Lohithaswa S, Shashidharan SP, Chidurala S, Diviti S, Patel D, Vadlamudi G, Obeid T, **Pogue JM**, Lephart PR, Martin ET, Flanagan E, Rybak MJ, Kaye KS. Risk Factors for

Vancomycin-resistant *Enterococcus faecalis* bacteremia: a case-case-control study. APIC 2012. San Antonio, TX

34. **Pogue JM**, Mynatt R, Marchaim D, Zhao JJ, Moshos J, Sunkara B, Chopra T, Chidurala S, Kaye KS. Impact of automated alerts on time to appropriate therapy among patients with Gram-negative bacteraemia. [platform presentation]. ECCMID 2012. London, UK.

33. Chopra T, Johnson PC, Chalana I, Tamam Z, Mohammed M, Alkatib S, Tansek R, Chaudhry K, BS, Marchaim D, Zhao JJ, **Pogue JM**, Dhar S, Kaye KS. Risk Factors Associated with Extended-Spectrum  $\beta$ -Lactamase (ESBL) Blood Stream Infection (BSI). IDSA 2011. Boston, MA.

32. **Pogue JM**, Marchaim D, Chopra T, Bheemreddy S, Lee J, Ahmad F, Chaudry A, Kaye KS. Evaluation of the potential impact of a carbapenem de-escalation program at the Detroit Medical Center (DMC). IDSA 2011. Boston, MA.

31. Hayakawa K, Marchaim D, Sunkara B, Kamatam S, Vahia A, Kodlipet Jagadeesh K, **Pogue JM**, Lephart PR, Martin ET, Rybak MJ, Kaye KS. Comparison of the Risk Factors for Co-colonization with Methicillin-Resistant *Staphylococcus aureus* (MRSA): VR E. *faecalis* vs. VR E. *faecium*. IDSA 2011. Boston, MA.

30. Hayakawa K, Marchaim D, Lephart PR, **Pogue JM**, Sunkara B, Moshos J, Jagadeesh KK, Kotra H, Hasan A, Suhrawardy U, Osunlana AM, Swan J, Patel S, Levine M, Yee V, Ahmad F, Lepakshi Reddy SM, Ku K, Kumar S, Yerramalla Y, Tiwari N, Mustapha M, Martin ET, Rybak MJ, Kaye KS. Risk Factors for Co-colonization of Vancomycin-Resistant *Enterococcus faecalis* and Methicillin-Resistant *Staphylococcus aureus* (MRSA): a Multivariate Analysis. ICAAC 2011. Chicago, IL.

29. Judge T, **Pogue JM**, Marchaim D, Lephart PR, Ho K, Jagadeesh KK, Kamatam S, Parveen S, Tiwari N, Nanjireddy P, Bheemerreddy S, Beidron C, Reddy SML, Khammam V, Chalana IK, Tumma SA, Zhao JJ, Mynatt RP, Rybak MJ, Kaye KS, Hayakawa K. Risk Factors for Daptomycin-nonsusceptible Vancomycin-resistant *Enterococci*: a case-case control study. ICAAC 2011. Chicago, IL.

28. Martin ET, Tansek R, Collins VL, Hayakawa K, Sunkara B, Abreu-Lanfranco O, Chopra T, Lephart PR, **Pogue JM**, Dhar S, Kaye KS, Marchaim D. The "CRE score": a bedside score to shorten the time to initiation of effective therapy for carbapenem-resistant *Enterobacteriaceae*. ICAAC 2011. Chicago, IL.

27. Collins VL, Marchaim D, **Pogue JM**, Moshos J, Bheemreddy J, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Irfan Memon B, Mynatt RP, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz SL, Carmeli Y, Kaye KS. The efficacy of carbapenems, including ertapenem, compared to alternative therapies for bloodstream infections (BSI) caused by extended-spectrum  $\beta$ -lactamase (ESBL) producing *Enterobacteriaceae*. ICAAC 2011. Chicago, IL.

26. Marchaim D, Bhargava A, Bogan C, Tansek R, Abreu-Lanfranco O, Lephart PR, **Pogue JM**, Chopra T, Hayakawa K, Sunkara B, Dhar D, Perez F, Bonomo RA, Kaye KS. Importance of Recent Antibimicrobial exposure as a predictor for carbapenem-resistant *Enterobacteriaceae* (CRE) isolation. ICAAC 2011. Chicago, IL.

25. Veltman J, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, **Pogue JM**, et.al. Impact of consolidative antimicrobial therapy on mortality in patients with blood stream infections (BSIs) due to extended spectrum beta-lactamase-producing pathogens. SHEA 2011. Dallas, TX.

24. Chopra T, Johnson PC, Chalana I, Temam Z, Mohammed M, Alkatib S, Tansek R, Chaudhry K, Marchaim D, Zhao JJ, **Pogue JM**, Dhar S, Kaye KS. Risk factors associated with ESBL bloodstream infections. SHEA 2011. Dallas, TX.
23. Chopra T, Johnson PC, Doshi H, Zhao JJ, **Pogue JM**, et.al. Epidemiology and Risk Factors of Patients with Blood Stream Infection (BSI) due to *Acinetobacter baumannii* (AB) – A Multicenter Case-Control Study. SHEA 2011. Dallas, TX.
22. Lynch Y, Bowman H, Rodriguez V, Veltman J, Tansek R, Abreu-Lafranco O, Marchaim D, Hayakawa K, Dhar S, Zhao JJ, **Pogue JM**, Lephart P, Alangaden G, Kaye KS, Chopra T. Epidemiology of non-bloodstream sterile site infections ESBL producing organisms at the Detroit Medical Center. SHEA 2011. Dallas, TX.
21. Hayakawa K, Marchaim D, **Pogue JM**, et.al. Co-colonization of Vancomycin-resistant *E. faecalis* and methicillin-resistant *S. aureus* at the Detroit Medical Center. SHEA 2011. Dallas, TX.
20. Hayakawa K, **Pogue JM**, Lephart PR, et.al. Growing prevalence of *Providencia stuartii* at Detroit Medical Center 2005-2009. SHEA 2011. Dallas, TX.
19. Hayakawa K, Marchaim D, **Pogue JM**, et.al. Epidemiology and Risk Factors for Bacteremia due to Vancomycin-resistant *Enterococcus* (VRE): *E. faecalis* compared to *E. faecium*. SHEA 2011. Dallas, TX.
18. **Pogue JM**, Marchaim D, Mynatt R, Zhao JJ, Abreu-Lafranco O, Bheemreddy S, Sunkara B, Hayakawa K, Chopra T, Dhar S, Kaye KS, Lephart PR. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant *Enterococcus* (VRE) at the Detroit Medical Center (DMC). SHEA 2011. Dallas, TX.
17. **Pogue JM**, Marchaim D, Lephart PR, Mynatt R, Zhao JJ, Bheemreddy S, Sunkara B, Moshos J, Hayakawa K, Chopra T, Dhar S, Kaye KS. Extended-spectrum beta-lactamase (ESBL)-producers and piperacillin/tazobactam in the era of lowered break-points and no confirmatory tests. SHEA 2011. Dallas, TX.
16. Marchaim D, Abreu-Lafranco O, Taylor AR, Bheemreddy S, Sunkara B, Bhargava A, Manickam P, Moshos J, Chevalier T, Bohlinger C, Robinson P, Han JI, Toftey B, Rice K, Dzeiken B, Semproch L, Preney K, Flanagan E, Hayakawa K, Chopra T, **Pogue JM**, Lephart PR, Kaye KS, Marchaim D Hospital Bath Basins are Frequently Contaminated with Multi-Drug Resistant Human Pathogens. SHEA 2011. Dallas, TX.
15. Campbell M, Sunkara B, Chugh N, Poona A, Wilson MN, Moshos J, Bheemreddy S, Ku K, Singh K, Chopra T, Hayakawa K, Abreu-Lafranco O, Lephart PR, **Pogue JM**, Dhar S, Kaye KS, Marchaim D. Trimethoprim/Sulfamethoxazole Compared to Daptomycin or Linezolid for the Treatment of Infections due to Methicillin-Resistant *Staphylococcus aureus*. SHEA 2011. Dallas, TX.
14. Ku K, Moshos J, Beemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Chopra T, Hayakawa K, Abreu-Lafranco O, Lephart PR, **Pogue JM**, Dhar S, Kaye KS, Marchaim D. Colistin versus tigecycline for the treatment of *Acinetobacter baumannii* and/or carbapenem resistant *Enterobacteriaceae* infections. SHEA 2011. Dallas, TX.

13. Marchaim D, Perez F, Hayakawa K, Manickam P, Lephart P, Bhemreddy S, Blunden C, Hujer A, Rudin S, Shango M, Campbell M, Varkey J, Patel D, Chopra T, **Pogue JM**, Dhar S, Bonomo RA, Kaye KS. Predictors and outcomes of patients with carbapenem-resistant Enterobacteriaceae co-colonized with *Acinetobacter baumannii* or *Pseudomonas aeruginosa*. SHEA 2011. Dallas, TX.
12. Johnson PC, Kaye KS, Marchaim D, Cooper CC, Lephart P, Hayakawa K, **Pogue JM**, Zhao JJ, Dhar S, Chopra T. Clinical Significance of Single Versus Multiple Positive Blood Cultures in Patients with. IDSA 2010. Vancouver, BC.
11. Lee J, Kaye KS, Marchaim D, Yee V, Zhao J, Chopra T, Lephart P, **Pogue JM**. Incidence of and risk factors for colistin associated nephrotoxicity at the Detroit Medical Center. ICAAC 2010. Boston, MA.
10. Kullar R, Davis SL, **Pogue JM**, Zhao JJ, Levine DP, Kaye KS, Rybak MJ. Evaluation of a clinical pathway for the treatment of MRSA bacteremia with an MIC of >1 to vancomycin. ICAAC 2010. Boston, MA
9. Marcham D, Perez F, Hayakawa K, Lephart P, Bhemreddy S, Blunden C, Hujer AM, Rudin S, Endimiani A, Bonomo RA, SHango M, Slim J, Campbell M, Varkey J, Chen T, Hothi JP, **Pogue JM**, Boikov D, Salimnia H, Chopra T, Zhao JJ, Dhar S, Kaye KS. Outcomes and genetic relatedness of carbapenem resistant enterobacteriaceae at the Detroit Medical center. ICAAC 2010. Boston, MA.
8. Marchaim D, Bhemreddy S, Lemanek L, Sengstock D, Bogan C, Ku K, Hasan A, Lee J, Khandker N, Blunden C, Moshos J, Geffert SF, Moody M, Rahbar H, Wang Y, Ahmad F, Lephart P, Malani A, Jagarlamudi R, Tansek R, Chopra T, Hayakawa K, **Pogue JM**, Dhar S, Kaye KS. The massive burden of multi-drug resistant Gram-negative organisms on hospitals by patients admitted from long term care facilities. ICAAC 2010. Boston, MA.
7. Chopra T, Zhao J, Tansek R, BS, Hatahet D, Hothi J, Chaudry K, **Pogue JM**, Rahbar H, Chen T, Truong T, Rodriguez V, Ellsworth J, Bernabela L, Bhargava A, Marchaim D, Alangaden G, Kaye KS. Impact of Empiric Cefepime Therapy on Mortality among patients with Blood Stream Infection (BSI) due to extended spectrum  $\beta$ -lactamase-producing pathogens (ESBLs). ECCMID 2010. Vienna, Austria
6. Chopra T, Hothi J, Marchaim D, Slim J, Chaudry K, Khandker N, Tansek R, Dhar S, Zhao J, **Pogue JM**, Kaye KS. Risk factors and outcomes associated with bloodstream infection due to *Acinetobacter baumannii* resistant to both carbapenems and ampicillin/sulbactam. Fifth Decennial: International Conference on Health-Care Associated Infections 2010. Atlanta, GA.
5. Marchaim D, **Pogue JM**, Hothi J, Chopra T, Dhar S, Slim J, Blunden C, Reid D, Moshos J, Benoit J, Hafeez W, Flanagan E, Alangaden G, Kaye KS. Outbreak of Colistin-Resistant Enterobacteriaceae at the Detroit Medical Center. Fifth Decennial: International Conference on Health-Care Associated Infections 2010. Atlanta, GA.
4. Saely S, Kaye KS, Fairfax M, Chopra T, **Pogue JM**. Risk factors for extended spectrum beta-lactamase producing *Klebsiella Pneumoniae* (ESBL): A focus on previous antibiotic exposure (PAE). ICAAC 2009. San Francisco, CA.
3. Reddy T, Chopra T, **Pogue JM**, Alangaden G, Salimnia H, Shar S, Kaye KS. Trends in Antimicrobial Resistance in *Acinetobacter baumannii* (ACB) in a Detroit Area Health System. ICAAC 2009. San Francisco, CA.

2. Kullar R, Leonard S, Davis S, Delgado G, Wahby K, **Pogue JM**, Sheth A, Shah P, Falcione B, Rybak M. Validation of a high-trough vancomycin nomogram to achieve trough concentrations of 15-20 mg/L. ECCMID 2009. Helsinki, Finland.

1. **Pogue JM**, DePestel DD, Pleva M, Newton D, Carver, P. Determination of optimal antibiogram data to utilize in optimizing empiric Gram-negative antibacterial therapy for hospital-acquired pneumonia and bacteremia. ASHP clinical midyear meeting 2007. Las Vegas, NV.

### **Clinical and Research Training Experience:**

**Co-Director, Infectious Diseases Clinical Practice and Translational Research Fellowship** 2024 – present

- University of Michigan College of Pharmacy

**Director, Infectious Diseases PGY-2 Residency** 2009 – 2013

- Detroit Receiving Hospital; Detroit Medical Center

**Preceptor, PGY-2 residents (Infectious Diseases/Antimicrobial Stewardship)** 2008 – 2019

- Practice site: Sinai-Grace Hospital; Detroit Medical Center
- PGY-2 residents precepted
  - Detroit Medical Center Infectious Diseases PGY-2
  - Michigan Medicine Infectious Diseases PGY-2
  - Harper University Hospital Pharmacotherapy PGY-2
  - Detroit Receiving Hospital Critical Care PGY-2
  - Detroit Receiving Hospital Emergency Medicine PGY-2

**Preceptor, PGY-1 Pharmacy Practice Residents (Infectious Diseases/Stewardship)** 2008 – 2019

- Practice site: Sinai-Grace Hospital; Detroit Medical Center
- PGY-1 Residents precepted:
  - Sinai-Grace Hospital
  - Harper University Hospital
  - Detroit Receiving Hospital

**Preceptor, Antimicrobial stewardship and Infectious Diseases APPE rotations.** 2008 – 2019

- Practice site: Sinai-Grace Hospital; Detroit Medical Center
- Students precepted:
  - Wayne State University College of Pharmacy and Health Sciences
  - University of Michigan College of Pharmacy
  - University of Pittsburgh College of Pharmacy
  - Lake Erie College of Osteopathic Medicine (LECOM) School of Pharmacy

### **Organization Committee Involvement and Leadership:**

**Society of Infectious Diseases Pharmacists (SIDP):**

- President (2018 – 2021)
  - Immediate Past President (2020 – 2021)
  - President (2019 – 2020)
  - President- Elect (2018 – 2019)
- Strategic Planning Committee (2020 – 2021)
  - Board Liaison (2020 – 2021)

- Annual Report Committee (2020 – 2021)
  - Board Liaison (2020 – 2021)
- Nominations and Bylaws Committee (2020 – 2021)
  - Board Liaison (2020 – 2021)
- Website committee (2018- 2019)
  - Board Liaison (2018 – 2019)
- Social Media Committee (2018 – 2019)
  - Board Liaison (2018 – 2019)
- Publications and Podcasts Committee (2018 – 2019)
  - Board Liaison (2018 – 2019)
- Inter-organization and Engagement (2019 – 2021)
  - Board Liaison (2019 – 2021)
- Policy and Governmental Affairs Committee (2019 – 2020)
  - Board Liaison (2019 – 2020)
- Programs (ID Week) Committee (2013 – 2014, 2019 – 2020)
  - Board Liaison (2019 – 2020)
- Guidelines committee (2022 – 2026)
  - Past Chair (2024 – 2026)
  - Chair (2023 – 2024)
  - Vice Chair (2022 – 2023)
- Membership Committee (2009 – 2010)
- Internet committee (2009 – 2010, 2013 – 2014, 2017 – 2018)
  - Vice Chair (2017 – 2018)
- Community Antimicrobial Stewardship Committee (2014 – 2015)
- Research Committee (2016 – 2018)
- SIDPEC committee (2016 – 2018)

**United States Committee on Antimicrobial Susceptibility Testing (USCAST):**

- Executive Committee Member (2022 – Present)
  - Chairman (2022 – Present)
- Member (2019 – Present)
- Advisor (2016 – 2018)

**American College of Clinical Pharmacists (ACCP):**

- ID PRN research Committee (2016 – 2019)
  - Chair (2017 – 2018)
  - Mentor – Justin Moore (2020 – Present)
- Faculty Panel Chair for IDSAP (2018 – 2019)

**Society for Healthcare Epidemiology of America (SHEA):**

- Research Committee (2022 – Present)
- Antimicrobial Stewardship Committee (2018 – 2021)
  - Co-chair-engaging critical access hospitals subcommittee (2019 – 2021)

**Detroit Medical Center:**

- Member, Antimicrobial Subcommittee (2008 – 2019)
  - Pharmacy lead and co-chair (2017 – 2019)
- Residency Steering Committee (2009 – 2013)

**Sinai-Grace Hospital:**

- Medication Use Committee Member (2009 – 2019)
- Antimicrobial Stewardship Team Lead (2009 – 2019)

- Residency Advisory Committee (2009 – 2019)
- Infection Control Committee (2009 – 2019)

**Tenet Antimicrobial Stewardship Committee Member (2015 – 2019)**

**Vanguard Health Systems**

- System coordinator Antimicrobial Stewardship (2011 – 2013)

**Michigan Medicine**

- Antimicrobial Subcommittee (2007 – 2008; 2019 – Present)
  - Secretary 2007 – 2008

**University of Michigan College of Pharmacy**

- Honor Council (2025 – Present)
- BSPS Curriculum Committee (2022 – Present)
- Admissions Committee (2019 – Present)
- Faculty Development Committee (2021 – 2023)
  - Co-chair (2021-23)

**Michigan Department of Health and Human Services**

- Antimicrobial Stewardship and Antimicrobial Resistance Pharmacy Consultant (2022- Present)

University of Michigan Investigational Review Board Member (2023 – 2024)

**Nontraditional Educational Experiences:**

**Podcasts:**

- SIDP Breakpoints (2019 – Present)
  - “The Itch” An SIDP Podcast Miniseries on Penicillin Allergy (2019)
  - 5 Ways Hospital Pharmacists Can Be Antibiotics Aware (2019)
  - What is Happening Right Now? COVID-19 Challenges and Silver Linings (2020)
  - A Lung Time Coming: Controversies in Community Acquired Pneumonia (2021)
  - Expectation vs. Reality: An Insider Look at the OVERCOME and MERINO-2 trials (2022).
  - 5 part Mini-series on Antimicrobial Susceptibility Breakpoints (2023).
  - Tetracyclines (2024)
- Society for Healthcare Epidemiology of America (SHEA) Podcasts (2020)
  - COVID-19: Involving Antimicrobial Stewardship Programs (2020)
- Pharmacy to Dose: The Critical Care Podcast (2023)
  - The Mercy Trial

**Blogs:**

- IDStewardship (2016 – 2017)
  - [Top 5 Unanswered questions about the management of invasive infections due to multidrug resistant Gram-negative bacteria](#) (2016)
  - [Nephrotoxicity: Piperacillin-Tazobactam Plus Vancomycin Versus Cefepime Plus Vancomycin](#) (2017)

**Editorial Boards:**

Antimicrobial Stewardship & Healthcare Epidemiology 2021 – Present

Open Forum in Infectious Diseases. 2018- Present.

Antimicrobial Agents and Chemotherapy. 2017 – Present.

Infectious Diseases and Therapy. 2017 – Present

Contagion Live. 2017 – Present

Wellspring Infectious Diseases. 2019 – Present.

Pharmacy Practice News. 2017 – 2019.

Associate Editor. Clinical and Biomedical research. 2014 – 2016

**Peer Reviewer:**

Journal of the American Medical Association (JAMA)

Lancet Infectious Diseases

Clinical Infectious Diseases

Antimicrobial Agents and Chemotherapy

Journal of Antimicrobial Chemotherapy

Pharmacotherapy

Annals of Pharmacotherapy

Journal of Clinical Microbiology

Diagnostic Microbiology and Infectious Diseases

BMC Infectious Diseases

Open Forum in Infectious Diseases

Clinical Microbiology and Infection

Expert Review of Anti-infective Therapy

Virulence

**Awards and Honors:**

Infectious Diseases Pharmacotherapy Paper of the Year Award, Society of Infectious Diseases Pharmacists (2025).

Distinguished Service Award, Society of Infectious Diseases Pharmacists (2024).

Fellow, Society of Infectious Diseases Pharmacists (2022).

Fellow, American College of Clinical Pharmacists (Awarded 2021).

Covid-19 Coalition member. MJH Life Sciences™ 2020.

Society of Infectious Diseases Pharmacist Outstanding Clinical Practice in Infectious Diseases Pharmacotherapy Award. 2017.

Lamp Award for Most Outstanding Basic Sciences Professor, Wayne State University School of Medicine. 2013.

Preceptor of the Year, University of Michigan College of Pharmacy. 2011.

Graduated Magna cum Laude. University of Pittsburgh School of Pharmacy. 2006.

Dean's List. University of Pittsburgh School of Pharmacy. 2002 – 2005.

Patient counseling competition winner. University of Pittsburgh School of Pharmacy. 2003, 2004.

**Current Affiliations and Memberships:**

United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Society of Infectious Diseases Pharmacists

Society for Healthcare Epidemiology of America

European Society of Clinical Microbiology and Infectious Diseases

American College of Clinical Pharmacists

- Infectious Diseases Practice and Research Network

Rho Chi Honor Society

**References available upon request**